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ABSTRACT
Background
Myocardial infarction remains a major health problem, despite recent improvements in 
detection and treatment. Infarct size is a major determinant of future mortality and morbidity. 
Management strategies aimed at limiting infarct size, beyond what is achieved with early 
revascularization in combination with platelet stabilization, could be of great prognostic 
importance.	 Although	 opening	 of	 the	 infarct-related	 artery	 is	 mostly	 beneficial,	 it	 also	
initiates	 harmful	 processes	 that	 contribute	 to	 the	 final	 infarct	 size,	 so	 called	 reperfusion	
injury. When performing studies aiming at myocardial protection, it is important to have 
methods	that	accurately	quantify	ischemic	but	viable	myocardium	and	the	final	infarct	size.	
Postconditioning, a method that consists of cycles of brief reperfusion and ischemia during 
early stages of revascularization, seems to limit reperfusion injury. Further knowledge is 
important	 for	 understanding	 how	 efficient	 this	 technique	 is	 and	 if	 the	 protection	 leads	 to	
long-lasting	benefits.
 
Methods and results
Study I investigated if postconditioning in addition to primary percutaneous coronary 
intervention (PCI) would limit infarct size and improve left ventricular ejection fraction 
(LVEF), compared with standard PCI. This was determined with cardiovascular magnetic 
resonance (CMR) after one week in 76 patients with ST-elevation myocardial infarction 
(STEMI). There was no difference in infarct size and LVEF within the total study population. 
Postconditioning	did,	 however,	 have	 a	beneficial	 effect	 on	final	 infarct	 size	 and	LVEF	 in	
patients with the largest volumes of myocardium at risk (MaR). 
Study II investigated if the results from study I were consistent during long-term follow-up in 68 
patients. In order to quantify infarct size and LVEF, the patients were re-examined with CMR 
at three and 12 months. There was no difference between patients who were postconditioned 
and those who underwent ordinary PCI in the complete study group. Postconditioned patients 
in the upper quartile of MaR did, however, still have less myocardial damage and improved 
LVEF after one year.
Study III	compared	MaR	estimated	with	a	new	modified	contrast-enhanced	CMR	sequence	
one week after admission with the reference standard method, myocardial perfusion single-
photon emission computed tomography (SPECT), in 16 patients with STEMI. There was a 
good correlation between the two methods. 
Study IV investigated 21 patients with STEMI one week after revascularization with CMR. 
T2-weighted (edema) images were compared with contrast-enhanced CMR sequence for the 
assessment of MaR. A strong agreement was found between the two methods. 
Conclusions
Postconditioning did not decrease infarct size or improve LVEF one week or 12 months 
after	the	procedure	in	all	patients	with	first	time	STEMI	subjected	to	this	method.	Patients	
with	 large	MaR	 seemed,	 however,	 to	 have	 a	 consistent	 benefit	 over	 time	 in	 the	 form	 of	
smaller infarct sizes and improved LVEF. There is a strong agreement between the newly 
developed contrast-enhanced CMR sequence compared with both reference standard SPECT 
and T2-weighted edema images. The implication is that the new technique can be used 
for	quantification	of	MaR	and	final	 infarct	 size	 in	patients	with	STEMI,	 through	a	 single	
investigation performed several days after the event.
Peder Sörensson
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SAMMANFATTNING
Bakgrund
Hjärtinfarkt är ett kvarstående hälsoproblem trots betydelsefulla förbättringar i handläggningen 
i form av tidig revaskularisering. Hjärtinfarktens storlek har stor betydelse för patientens 
framtida prognos. Strategier som kan minska hjärtinfarktens storlek är därför viktiga tillägg 
till	 tidig	 revaskularisering.	 Även	 om	 ett	 återställt	 kranskärlsblodflöde	 huvudsakligen	 är	 av	
godo initierar det också processer som leder till hjärtcellsdöd, så kallad ”reperfusionsskada”. 
Vid studier av möjligheten att reducera sådana skador är det av största vikt att förfoga över 
metoder som tillförlitligt kan mäta skillnaden mellan det hotade myokardområdet (riskarean) 
och den slutgiltiga hjärtmuskelskadan. S.k. postkonditionering, upprepade cykler av återskapat 
kranskärlsblodflöde	med	mellanliggande	avstängning	av	flödet,	är	en	metod	som	tycks	minska	
reperfusionsskadan. Ytterligare studier behövs emellertid för att slutgiltigt värdera effekten av 
denna åtgärd.
Metoder och resultat
Studie I undersökte om postkonditionering i samband med perkutan koronarintervention 
(s.k. ballongsprängning; PCI) jämfört med enbart PCI utan postkonditionering minskar 
hjärtinfarktstorleken och ökar vänsterkammarens funktion mätt med magnetkamerateknik 
(MR) efter en vecka hos 76 patienter med förstagångsinfarkter. En sådan effekt kunde inte 
verifieras	i	den	totala	studiepopulationen.	Dock	utvecklade	postkonditioneringspatienter	med	
stora riskareor mindre hjärtinfarkter och hade en bättre hjärtmuskelfunktion jämfört med 
motsvarande kontrollindivider. 
Studie II studerade de långsiktiga effekterna av postkonditionering. Efter tre och 12 månader 
återundersöktes 68 patienter från Studie I med MR. Liksom i den första studien förelåg 
ingen skillnad mellan grupperna vad avser infarktstorlek eller vänsterkammarfunktion, men 
postkonditionerade patienter med stora riskareor hade fortfarande mindre hjärtmuskelskador 
och bättre vänsterkammarfunktion jämfört med sina motsvarande kontrollpersoner. 
Studie III:	 Riskarean	 hos	 16	 patienter	 med	 hjärtinfarkt	 bestämdes	 med	 en	 ny	 modifierad,	
kontrastförstärkt MR-sekvens en vecka efter insjuknandet och jämfördes med riskarean 
uppmätt	med	hjärtscintigrafi	som	referensmetod.	Överensstämmelsen	mellan	de	två	metoderna	
var god.
Studie IV: Tjugoen patienter med hjärtinfarkt genomgick MR-undersökning av hjärtat en vecka 
efter ballongsprängning. De då erhållna T2-viktade ödembilder jämfördes med motsvarande 
fynd	 med	 den	 modifierade	 kontrastförstärkta	 MR-sekvensen.	 Även	 här	 förelåg	 en	 god	
överensstämmelse. 
Slutsats
Postkonditionering hade, i studiepopulationen som helhet, ingen effekt på hjärtinfarktstorlek 
eller vänsterkammarfunktion, varken en vecka eller 12 månader efter en förstagångsinfarkt. 
Patienter med stora riskareor tycks emellertid ha nytta av postkonditionering, som hos dessa 
minskade hjärtmuskelskadan och förbättrade vänsterkammarfunktionen på ett bestående 
sätt. Det förelåg en god överensstämmelse mellan den nyutvecklade, kontrastförstärkta MR-
sekvensen	jämfört	med	både	referensmetoden	hjärtscintigrafi	och	T2-viktade	ödembilder	vad	
avser fastställande av det hotade myokardområdet. Fortsättningsvis kan den nya sekvensen 
användas i framtida infarktstudier som behöver mäta både riskarea och infarktstorlek samt 
utföras	med	endast	en	undersökning	flera	dagar	efter	det	akuta	insjuknandet.
         Effects of postconditioning in myocardial infarction
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LIST OF ABBREVIATIONS
ACEi/ARB angiotensin converting enzyme inhibitor/ angiotensin receptor blocker
ACS acute coronary syndrome
ADP adenosine diphosphate
ATP adenosine triphosphate
CABG coronary artery bypass grafting
CK creatine kinase
CKMB creatine kinase isoenzyme MB
CMR cardiac magnetic resonance
DTPA diethylenetriamine penta-acetic acid
ECG electrocardiography
Erk1/2 extracellular regulated kinase
GP glycoprotein
GSK3β	 glycogen	synthase	kinase-3β
IS infarct size
LAD left anterior descending artery
LCx	 left	circumflex	artery
LDL  low density lipoprotein
LGE late gadolinium enhancement
LV left ventricle
LVEF left ventricular ejection fraction
MaR myocardium at risk
MI myocardial infarction
MPS myocardial perfusion SPECT
MVO microvascular obstruction
mPTP mitochondrial permeability transition pore
NO nitric oxide
NOS NO synthase
PCI percutaneous coronary intervention
PET positron emission tomography
PKC/G protein kinase C/G
PI3K phosphatidylinositol-3-kinase
RCA right coronary artery
RISK reperfusion injury salvage kinases
ROI region of interest
ROS  reactive oxygen species
SAFE survivor activating factor enhancement
SNR signal-to-noise ratio
SPECT single-photon emission computed tomography
CE-SSFP contrast-enhanced steady-state free precession
STEMI ST-elevation myocardial infarction
STIR short inversion time inversion recovery
99mTc technetium
TE echo time
TI inversion time
TIMI thrombolysis in myocardial infarction 
TNFα	 Tumor	necrosis	factor	α
TR repetition time
TTC triphenyltetrazolium chloride
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INTRODUCTION
Acute myocardial infarction
Worldwide coronary heart disease remains a major health problem despite substantial 
improvements in detection and treatment.1 In 2010 the SWEDHEART registry, comprising 
information on all Swedish hospital admissions for acute myocardial infarction (MI), recorded 
approximately 19,600 patients of whom 5,100 had ST-elevation myocardial infarctions 
(STEMI).	The	risk	profile	of	patients	with	STEMI	has	changed	during	1995-2010	with	an	
increasing proportion of subjects with obesity, treated hypertension and hyperlipidema and 
also smokers. The proportion of patients with diabetes mellitus has remained around 20 
% persistently. Reperfusion treatment, either by percutaneous coronary intervention (PCI) 
or thrombolysis, was performed in 70 % of the STEMI population during 1995-2004 and 
successively increased to 90 % in 2010, above all in the form of primary PCI. During the 
period 1995-2010, there has been an increase in the short- and long-term survival of patients 
with STEMI regardless of sex and age. This is most likely the result of improved reperfusion 
treatment, more aggressive anti-platelet therapy, increased use of betablockers, statins and 
angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers.2 Still, 
many STEMI patients develop large areas of myocardial necrosis and infarct size is a 
major determinant of subsequent mortality and morbidity.3, 4 Accordingly, early instituted 
therapeutic strategies aimed at limiting infarct size should be of great prognostic importance 
as a supplement to current management focused on primary revascularization in combination 
with platelet stabilization.5 The development of such treatment modalities is critically 
dependent on methods that accurately determine the size of the ischemic myocardium at risk 
(MaR)	and	final	infarct	size.	Moreover,	these	methods	must	be	feasible	to	use	in	connection	
to the acute revascularization procedure, usually a PCI.
Pathophysiology
All acute coronary syndromes (ACS) comprising unstable angina, non-STEMI and STEMI, 
share a common pathophysiological sequence: the disruption of an atherosclerotic plaque 
leading to platelet aggregation, thrombus formation and a nearly or completely occluded 
coronary	artery.	This	causes	myocardial	ischemia	due	to	insufficient	blood	supply	in	relation	
to	 the	 demands	 of	 the	 jeopardized	myocardial	 area.	 If	 blood	 flow	 is	 not	 restored	within	
an appropriate time period the ischemia will result in cellular necrosis, which starts in the 
subendocardial myocardium and progresses like a “wave-front” towards the epicardial region, 
eventually developing into a transmural myocardial infarct.6, 7 The ischemic cardiomyocytes 
generate lactic acid from anaerobic metabolism, thereby reducing the intracellular pH which 
activates their sarcolemmal Na+-H+ channels exchanging H+ at the expense of intracellular 
Na+ accumulation. This is followed by an activation of the Na+-Ca2+ channel resulting in an 
increased intracellular Ca2+ concentration and elevated levels of Ca2+ in the mitochondria. 
At the same time, attempts to maintain the mitochondrial oxidative phosphorylation deplete 
adenosine triphosphate (ATP), which is broken down to adenosine diphosphate (ADP) and 
phosphate, resulting in high mitochondrial levels of phosphate. In the end, this will lead to 
Peder Sörensson
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increased mitochondrial membrane permeability and the loss of viability (myocyte necrosis or 
apoptosis) and release of large molecules like creatine kinases and troponins into the blood.8 
Myocardial injury initiates cellular and extracellular processes in the reperfusion phase 
leading	 to	cell	death,	 inflammation	and	scar	 formation.	Molecular,	cellular	and	 interstitial	
events, collectively termed LV remodeling, culminate in changes in the size, shape and 
function of the left ventricle (LV). The LV remodeling process thereby involves the entire 
LV: the injured myocardium, the surrounding border zone and the remote myocardium.   
 
Diagnosis and current treatment
When managing patients with STEMI, the goals are early diagnosis, the earliest possible 
institution of reperfusion therapy and optimal secondary prevention.9 The diagnosis of an 
acute myocardial infarction is, according to internationally established criteria, based on 
typical symptoms in combination with ECG changes and the release of myocardial enzymes, 
in particular troponins.10 The initial diagnosis of acute coronary occlusion can be made 
using several different techniques and methods. Classic symptoms like severe chest pain, 
referred pain in either arm or the jaw and/or acute onset of shortness of breath are still the 
best indications of coronary occlusion. Electrocardiography (ECG) in the acute setting has 
a	 fairly	 good	 sensitivity	 and	 specificity	 for	 acute	myocardial	 ischemia	 (ST-elevation,	 and	
T-wave changes) and necrosis (Q-wave development). Repeated ECG should be obtained if 
possible. Cardiac biomarkers, preferable high-sensitivity troponin I or T, are highly sensitive 
for myocardial necrosis. With strong suspicion from symptoms and ECG, one should not wait 
to see elevated biomarkers before the initiation of reperfusion treatment. Additional evidence 
from cardiac imaging regarding loss of viability or newly developed regional wall motion 
abnormalites will support the diagnosis of myocardial injury, but wall motion abnormalities 
are	not	specific	for	STEMI	and	may	be	due	to	ongoing	ischemia	or	an	old	infarction.10 
For patients with a clinical presentation of STEMI less than 12 hours and with persistent 
ST-elevation or new onset left bundle-branch block, early mechanical or pharmacological 
reperfusion should be performed. If available within a short time, primary PCI – i.e. 
angioplasty	and	stenting	without	prior	or	concomitant	fibrinolytic	 therapy	–	 is	considered	
the treatment of choice. Primary PCI decreases mortality and nonfatal re-infarctions and 
causes fewer haemorrhagic strokes compared with thrombolysis.11, 12 The procedure requires 
transportation to hospitals equipped for acute PCI which may delay the onset of reperfusion. 
It	is,	however,	always	preferred	if	the	PCI	can	be	performed	within	two	hours	after	the	first	
medical contact.12, 13 In patients presenting early with a large myocardium at risk (MaR), 
the delay should be shorter, and although not truly evidence-based a maximum of 90 min is 
recommended in such patients. Current guidelines stress the need for the shortest possible 
delay	between	the	first	medical	contact	and	the	onset	of	PCI,	preferrably	within	90	minutes	or	
less in all patients.9 In the absence of contraindications, the use of pre-hospital thrombolysis 
should	always	be	considered	if	the	time	to	admission	or	PCI	is	significantly	delayed.	
Activated platelets are critical to the mechanism following acute plaque rupture and thrombus 
formation.	Specific	and	potent	inhibition	of	platelet	activation	aims	to	protect	the	myocardium	
against ischemic events by maintaining the patency of the infarct-related coronary artery 
without	significantly	increasing	the	risk	of	major	bleeding.	Improved	clinical	outcomes	have	
         Effects of postconditioning in myocardial infarction
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been achieved by inhibiting platelet activation and aggregation.5, 14-19 Such therapy includes 
antithrombotic treatment with: a bolus dose of aspirin (320-500 mg), which inhibits the release 
of thromboxane A2 by the thrombocyte; a bolus dose of clopidogrel (300-600 mg) inhibiting 
the ADP receptor-mediated platelet activation and aggregation; intravenous glycoprotein 
(GP)	 IIb/IIIa	 inhibitors	which	 inhibit	 fibrogen	 binding	 to	 the	 receptor	 preventing	 platelet	
aggregation	 and	 finally	 intravenous	 unfractionated	 heparin	 or	 inhibitors	 of	 the	 thrombin	
platelet	receptor.	Recent	studies	show	that	bivalirudin	combines	a	comparable	efficacy	with	
a lower risk of bleeding complications, compared with GP IIb/IIIa inhibitors.20 Additional 
medical treatment, including beta-blockers, ACE inhibitors and aldosterone antagonists, aims 
at preventing early and late myocardial remodeling and decreasing the risk for arrythmias.21-
23 Lipid-lowering is also part of the standard therapy, reducing mortality and the likelihood 
for new coronary events by approximately 20 % per one mmol/l reduction of low density 
lipoprotein cholesterol.24  
Reperfusion injury
Even though reperfusion of an occluded coronary artery is a prerequisite for the salvage of 
ischemic	myocardium,	 the	 restoration	of	 coronary	blood	flow	 to	 the	vulnerable	myocytes	
leads	to	further	metabolic	and	biomechanical	injury	in	the	first	few	minutes	of	reperfusion.	
This phenomenon is referred to as reperfusion injury (Figure 1). Reperfusion injury can be 
defined	as	injury	(reversible	or	irreversible)	sustained	to	tissue	and	organs	after	the	onset	of	
reperfusion. Experimental evidence reveals that such injury may be limited by mechanical or 
pharmacological therapy initiated at the onset of reperfusion.25 
Molecular and cellular events underlying the ischemic reperfusion injury are complex, but 
several key pathophysiologic factors have emerged. Reperfusion leads to rapid normalisation 
of	ion	flux	and	pH	which	paradoxically	enhances	myocardial	cytotoxicity	by	activating	ion	
channels leading to the accumulation of intracellular sodium. High sodium concentrations 
further promote an increase in intracellular Ca2+ concentration, which causes myocyte 
hypercontractility, ATP depletion and myocardial stunning.27 Impaired endothelial function 
with	reduced	bioavailability	of	nitric	oxide	(NO)	which	under	normal	conditions	has	benefical	
and protective effects by eliciting vasodilatation, inhibiting platelet aggregation, inhibiting 
leukocyte adhesion and scavenging reactive oxygen species (ROS)28-30, is of importance in 
the process. Paradoxically, high concentrations of NO may, in the presence of ROS, mediate 
additional toxicity by the formation of the highly reactive species peroxynitrite.31 Endothelial 
injury	 increases	 vascular	 permeability	 and	 recruitment	 of	 inflammatory	 cells.	 Cellular	
adhesion	molecules	promote	 the	 invasion	of	 inflammatory	cell	 into	 the	 tissue	 through	 the	
injured endothelium. Neutrophils in particular are toxic to the myocyte by secreting proteases, 
generating ROS and occluding the microvasculature.
The generation of free radicals through incomplete reduction of oxygen has been well 
described. ROS are highly reactive and can quickly inhibit the scavenging system of the 
myocytes. This in turn triggers cell injury by reactions with lipids, proteins and nucleic acids. 
The enzymes xanthine oxidase, NADPH oxidase and NO synthase are generators of free 
radicals in the reperfused heart.32 ROS triggers the opening of the myocardial permeability 
transition pore (mPTP). When the mPTP opens, this collapses the inner mitochondrial 
membrane potential, which is required to drive the oxidative phosphorylation, and this leads to 
further ATP depletion and cell death. 33, 34 The mPTP is a voltage- and Ca2+-dependent channel 
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located in the inner membrane of the mitochondria. Its opening increases permeability to 
solutes with molecular masses up to 1,500 Daltons.35 
In 1988 Cromptons et al36	were	the	first	to	propose	the	possible	involvement	of	the	mPTP	
in reperfusion injury in the heart. It was noted to be sensitive to calcium, oxidative stress, 
phosophate and ADP, all present during myocardial ischemia. The same group discovered 
that opening of the mPTP could be inhibited by the immunosuppressant drug cyclosporin-A 
through the cyclophiline-D matrix protein.37	Following	this,	Griffiths	et	al38 discovered that the 
mPTP	remained	closed	during	myocardial	ischemia	and	opened	during	the	first	few	minutes	
of	reperfusion,	thereby	defining	a	critical	time-window	for	cardioprotection.	However,	the	
mPTP still needs to be completely characterised.
There is general agreement on the fact that the reperfusion injury occurs very early 
after reperfusion based on the rapid formation of ROS that damage endothelial cells, 
Figure 1. The concept of reperfusion injury. During ischemia, irreversible cell injury leading 
to cell death occurs within the ischemic risk zone in a time-dependent manner. In the absence 
of reperfusion, ischemic injury would progressively kill more and more cells, eventually 
accounting for near total cell death (broken line). Reperfusion halts the process of ischemic 
cell death but in its early stages imposes injury that results in further cell death, beyond that 
due to the ischemic period: this is lethal reperfusion injury. The net result, however, is that 
the reperfused tissue sustains less cell death than would occur in ischemic tissue without 
reperfusion. Targeting cell death due to reperfusion has the potential to maximize cell salvage. 
Postconditioning applied at the onset of reperfusion might limit the extent of reperfusion injury 
and maximizes reperfusion salvage. Adapted from Garcia-Dorado and Piper.26
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rapid normalisation of tissue pH and the opening of the mPTP during early moments of 
reperfusion. Zweier et al39, 40 showed increasing levels of free radicals in rabbit hearts within 
10 seconds of the onset of reperfusion. These results demonstrated that ROS were produced 
in the hearts during ischemia and that free radical generation occurred within moments of 
reperfusion. A recent study in mice demonstrated limitation in infarct size development by 
ischemic postconditioning that was initiated as late as 30 minutes after the initial reperfusion, 
indicating that the time window for the reperfusion injury and effect of protective therapy 
might be longer than initially considered.41
Myocardial conditioning
Since the myocyte seems fairly resistent to prolonged ischemia reperfusion, injury has been 
suggested	as	a	substantial	contributer	to	the	final	infarct	size.42 Experimental studies targeting 
mediators	 of	 reperfusion	 injury	 report	 sizeable	 reductions	 of	 the	 final	myocardial	 injury,	
suggesting	 that	 processes	 induced	 by	 reperfusion	may	 contribute	 to	 30-50	%	of	 the	final	
infarct size.43 To be useful in clinical practice, reperfusion therapy has to be easy to implement 
in-	or	outside	the	hospital	and	safe,	and	must	not	significantly	delay	time	to	reperfusion.	Also,	
myocardial conditioning needs to be implemented in conjunction with revascularization 
therapy to further limit infarct size and potentially decrease future morbidity and mortality. 
Therapeutic strategies may include activation of endogenous protective signaling mechanisms 
either by local or remote ischemic or pharmacological conditioning of the myocardium. Such 
strategies can be initiated before the ischemic event (preconditioning), during the event 
(perconditioning) or after the onset of reperfusion (postconditioning). 
Ischemic conditioning
Preconditioning 
In 1986, Murry et al44 showed that myocardial infarct size could be reduced if the myocardium 
was exposed to brief episodes of myocardial ischemia and reperfusion before the index 
ischemia, a technique they named ischemic preconditioning. Anesthetised, open-chest dogs 
were	subjected	to	four	cycles	of	five	minutes	of	coronary	artery	occlusion	followed	by	five	
minutes of reperfusion before the onset of 40 minutes of occlusion followed by four days 
of	 reperfusion.	This	procedure	 resulted	 in	a	 significant	 limitation	of	 infarct	 size:	25	%	of	
that	seen	in	the	control	group.	Importantly,	collateral	blood	flow	did	not	differ	between	the	
two	groups.	This	finding	generated	a	massive	research	effort,	both	in	vivo	and	in	vitro,	to	
identify cellular and molecular pathways behind the cardioprotective effect.45 Successful 
preconditioning is dependent on two distinct “time windows”. Myocardial protection is 
activated within minutes by activating complex signalling cascades triggering the release 
of several mediators, including a number of survival kinases (see below). The effect of this 
“first	 time	window”	lasts	between	one	and	two	hours.	A	“second	time	window”	opens	24	
hours after the induction of ischemia and lasts for 48-72 hours.46, 47 The requirement for 
preconditioning limits its clinical use in patients with acute MI, but it can be utilized in 
different controlled situations such as in coronary artery by-pass grafting (CABG) or cardiac 
transplantation.48 
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Postconditioning
In 2003, Zhao et al49 performed a study on anesthetized open-chest dogs in which LAD was 
occluded during 60 minutes and reperfused for three hours. In a preconditioned group, LAD 
was	occluded	for	five	minutes	and	reperfused	for	10	minutes	before	the	prolonged	occlusion.	
In a second, postconditioned group, three cycles of 30 seconds reperfusion and 30 seconds of 
reocclusion preceded the three-hour-long reperfusion. Compared with controls, infarct size 
was	significantly	smaller	in	both	the	preconditioned	and	the	postconditioned	group.	Indeed,	
as depicted in Figure 2, postconditioning limited infarct size by more than 40 %. Endothelial 
function of the postischemic LAD, assessed using the maximal vasodilator response to 
acetylcholine,	was	significantly	greater	in	the	post-	and	preconditioned	groups.	
Similar	 infarct-limiting	 effects	 has	 been	 confirmed	 in	 different	 experimental	 models,	 for	
example about 50 % in canines and 25 % in rodents.50-53 The postconditioning algorithm 
differed between different animal models (from 10/10 seconds in mouse and rat up to 
60/60 seconds in rabbit) as did the ischemia/reperfusion time. In some studies performed 
in rabbits and rats, the outcome was similar in the postconditioned and control groups .53, 54 
Experimentally, the outcome of postconditioning in the presence of comorbidities (e.g. age, 
diabetes, hypertension and hyperlipidemia) has been variable, with some studies showing 
infarct limitation while others have been neutral in this respect.55 The postconditioning 
algorithm has not been consistent between different animal and clinical studies. The protocols 
have ranged from 30 to 90 seconds of reperfusion and ischemia and the number of cycles 
from two to four.56 
Coronary occlusion
Control
Precon
Postcon
60 min                        3h
5  10 min                           3h
                                            3h
30
25
20
15
10
5
0
Control Precon Postcon
p < 0.05
Infarct size
(% area at risk)
Figure 2. Infarct size limitation by pre- and postconditioning. Coronary occlusion followed 
by reperfusion is associated with infarct development in the ischemic risk zone (Control). 
Brief periods of ischemia and reperfusion performed either before index coronary 
occlusion (Precon=preconditioning) or immediately after index coronary occlusion 
(Postcon=postconditioning) can significantly limit infarct size. In animal models, such as 
the dog, subjected to coronary artery occlusion and reperfusion, either preconditioning or 
postconditioning can confer equivalent protection. Data from Zhao et al.49
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The advantage of postconditioning is that it can easily be implemented in clinical practice 
studying patients with STEMI. Postconditioning can be performed without delaying 
symptom-to-balloon time in connection to a primary PCI during which brief cycles of 
reperfusion and ischemia are instituted using the PCI balloon. In 2005, Staat et al57 performed 
a proof-of-concept study of postconditioning in patients with STEMI. The patients underwent 
primary PCI with direct stenting, with or without postconditioning applied as one minute of 
reperfusion followed by one minute of ischemia repeated four times. Area under the curve 
(AUC)	 of	 creatine	 kinase	 release	 over	 72	 hours	was	 significantly	 reduced	 (36	%)	 in	 the	
postconditioning group (Figure 3). The same group demonstrated reduction in infarct size by 
postconditioning using single-photon emission computed tomography (SPECT) six months 
after the acute event.58 This effect was associated with improved left ventricular ejection 
fraction (LVEF) after one year determined by echocardiography. Laskey et al59, 60 reported a 
significant	decrease	in	ST-segment	resolution	and	an	increased	coronary	blood	flow	reserve	by	
applying	two	ischemic	cycles	of	90	seconds	separated	by	three	–	five	minutes	of	reperfusion.	
All	patients	received	intracoronary	adenosine	before	coronary	flow	reserve	was	measured.			
  
Remote conditioning
That remote conditioning, i.e. brief episodes of ischemia and reperfusion in a remote tissue, 
can	protect	 the	myocardial	cells	 from	 the	harmful	effects	of	 sustained	 ischemia,	was	first	
demonstrated by Przyklenk et al59 in 1993. They demonstrated, in dogs, that brief episodes 
of	occlusion	of	 the	 left	circumflex	coronary	artery	 (LCx)	significantly	 limited	 infarct	 size	
following sustained occlusion of the left anterior descending artery (LAD). Following 
the initial discovery of remote conditioning, it was reported that brief periods of ischemia 
in distant organs such as skeletal muscle, kidney and intestine also induced myocardial 
preconditioning.60-62 It has been postulated that some, still unknown, humoral, neural 
or	 anti-inflammatory	 signal	 is	 activated	 in	 the	 conditioned	 organ	which	 then	 triggers	 the	
protection pathways of the heart. Remote conditioning can be effective when applied before 
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Figure 3. Top panel: Patients 
with STEMI treated with PCI 
(primary coronary interven-
tion) were randomly assigned to 
receive either no further inter-
vention (control) or four cycles 
of one min angioplasty balloon 
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or during the index ischemia in line with the effect of local conditioning. In 2002, Kharbanda 
et al63 demonstrated that remote preconditioning prevents ischemia-reperfusion injury in 
the human forearm and that it limits the extent of myocardial infarction in experimental 
animals, observations with important clinical potential. Protective effects in the heart by 
means of remote ischemia of the arm have been seen in patients undergoing CABG.64 Li et 
al65 used lower limb conditioning during replacement of rheumatic valves and reported lower 
levels of troponin I release. Recently, Bøtker et al66	demonstrated	a	significant	increase	in	
myocardial salvage index and increased LVEF in patients with STEMI subjected to remote 
perconditioning. Five minutes of arm-cuff ischemia followed by reperfusion was initiated in 
the ambulance and repeated four times before opening the coronary occlusion by means of 
primary PCI. 
Pharmacological conditioning
Since the discovery that pre- and postconditioning exert substantial protection during 
reperfusion, a growing number of pharmacologic agents with protective effects against 
reperfusion	injury	have	been	identified	and	investigated	in	experimental	studies.52, 67-70. The 
drug should be given before or at the time for reperfusion during the narrow window of 
reperfusion injury. The number of agents tested is large and includes NO donors, adenosine, 
bradykinin, inhalational anaesthetics, cyclosporine-A, erythropoietin, opioid agonists and 
endothelin.71-82 In general, these agents activate the same cardioprotective signalling pathways. 
So far, clinical trials have not shown overwelming results with these compounds. Many 
studies have been neutral and only a few partially successful.83, 84 Adenosine and an adenosine 
agonist were used in AMISTAD-I, -II (with thrombolysis) and ADMIRE (with PCI) trials.72, 
85, 86 In AMISTAD II, the patients given the higher dose of adenosine and early reperfusion 
(<3	hours)	had	significantly	smaller	final	infarct	sizes	measured	with	SPECT.	The	AMIHOT	
II trial using supersaturated oxygen limited the size of anterior infarcts.87 Recombinant 
atrial natriuretic peptide administration was used in the J-WIND trial and demonstrated 
small limitations in infarct size and improved LVEF after six months.73 In the other arm 
of	 J-WIND,	 nicorandil	 was	 without	 beneficial	 effect.	 The	 use	 of	 cyclosporin-A	 (inhibits	
the	mPTP	 through	 cyclophilin-D)	 as	 a	 intravenous	 bolus	 before	 reperfusion	 significantly	
limited	infarct	size	measured	with	cardiovascular	magnetic	resonance	(CMR)	five	days	after	
reperfusion, in a pilot study by Piot et al.76 A European multicenter trial with cyclosporin-A is 
presently	conducted	in	an	attempt	to	confirm	this	observation.	Recently	Lønborg	et	al75 used 
exanatide (glucagon-like-peptid-1 analog) before reperfusion and reported a larger salvage 
index in the treatment group and a trend in absolute infarct size reduction. 
Although hypothermia is not a pharmacological intervention, it is worth mentioning. The 
two major clinical trials (COOL-MI and ICE-IT) investigating mild hypothermia failed to 
show any reduction in infarct size (unpublished observations presented at the transcatheter 
cardiovascular therapeutics meeting,Washington 2004). A subgroup of patients who reached 
a	 temperature	of	<35	 °C	before	 reperfusion	had	 a	 significant	 reduction	 in	 infarct	 size.	 In	
2010, Götberg et al88 performed a pilot study showing promising results with smaller infarct 
sizes in relation to MaR and a smaller degree of microvascular obstruction (MVO) in patients 
randomized to hypothermia. 
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Potential mechanisms and pathways involved in ischemic conditioning    
 
The current paradigm proposes that ischemic conditioning stimulates a complex network 
of	 intracellular	 signalling	 pathways,	which	 in	 the	 end	 affects	 specific	 components	 of	 the	
mitochondria such as opening of the mitochondrial KATP channel and/or inhibition of 
the mPTP. In 2001, Xu et al89 suggested that mPTP may be a target for calcium-induced 
preconditioning	protection.	Subsequent	studies	have	confirmed	that	mPTP	inhibition	is	part	of	
the process of preconditioning in several different settings and species.90-94 Postconditioning 
is also believed to inhibit mPTP opening by regulating the levels of intracellular calcium, 
decreasing oxidative stress and increasing ATP levels, intracellular pH regulation, endothelial 
dysfunction	 and	 inflammation.95 Postconditioning delays the normalisation of tissue pH 
by delaying re-alkalinisation of the cardiomyocytes during reperfusion, which decreases 
intracellular calcium levels. This inhibits the opening of mPTP and early contraction of the 
myocytes;	a	sequence	supported	by	the	finding	that	administration	of	acidotic	buffer	during	
reperfusion limits infarct size in dogs.96 Postconditioning attenuates the generation of ROS 
which reduces intracellular and intra-mitochondrial calcium accumulation, inhibiting the 
opening	of	mPTP.	Furthermore,	postconditioning	may	have	an	anti-inflammatory	effect	by	
reducing the accumulation of neutrophils, diminishing endothelial activation and decreasing 
the	levels	of	tumor	necrosis	factor	(TNFα)	and	interleukin	(IL-6/8).97, 98
Three major potential pathways will be discussed below, the reperfusion injury salvage 
kinases (RISK) pathway, the survivor activating factor enhancement (SAFE) pathway and 
the sphingosine kinase pathway (Figure 4). The details of these pathways are not fully 
understood and there may be substantial cross-talk between them. Several other mechanisms 
and	pathways	have	been	suggested	as	influencing	prevention	of	ischemia-reperfusion	injury,	
but will not be further discussed in this thesis.
The RISK pathway
In 2002, Schulman et al100 demonstrated that classic autacoids such as adenosine, bradykinin 
and opioids trigger cardioprotection through different receptor-mediated mechanisms. 
Extracellular regulated kinase 1/2 (Erk1/2) and phosphatidylinositol-3-kinase (PI3K) 
inhibited	 glycogen	 synthase	 kinase-3β	 (GSK-3β)	 via	 phosphorylation	 of	 Akt,	 thus	
subsequently inhibiting the opening of mPTP. Via another signalling pathway, PI3K-Akt 
activates endothelial NO synthase (eNOS) to produce NO, which stimulates cytosolic protein 
kinas	G	(PKG)	and	mitochondrial	protein	kinas	C	(PKC-ε)	and	subsequently	opens	the	inner	
mitochondrial KATP channel, thus mediating cardioprotection through signalling ROS and/
or mPTP inhibition.51, 101-106	Specific	receptors	of	the	autacoids	have	different	effects	on	the	
cardioprotection cascade when they are activated or inhibited.
The SAFE pathway
The activation of the Survivor Activating Factor Enhancement (JAK-STAT) pathway has 
been proposed as an alternative cardioprotective cascade.107	TNFα	can	have	adaptive	effects	
depending on its concentration and to which of its two receptors it binds. Activation of exogenous 
or	endogenous	TNFα	at	the	time	of	reperfusion	initiates	the	activation	of	TNF	receptor-2	which	
phosphorylates the signal transducer and activator of transcriptin-3 (STAT-3). It is proposed 
that, after translocation to the nucleus, STAT-3 controls the transcription of factors that confer 
cardioprotection	by	inactivation	of	GSK-3β	or	direct	inhibition	of	mPTP.99, 108 
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The sphingosine kinase pathway
Activation of sphingosine kinase generates sphingosine-1-phosphate which seems to recruit 
other components of the RISK pathway.109, 110 On the other hand, sphingosine is a downstream 
mediator	of	TNFα	and	also	activates	STAT-3	for	 inhibition	of	 the	mPTP.111 The cross-talk 
between these pathways is probably substantial and not fully understood. 
Quantification of myocardial salvage
As mentioned above, the clinical outcome after an acute myocardial infarction depends 
on	 several	 factors	 including	 the	duration	of	 ischemia,	 the	 extent	 of	 collateral	 blood	flow,	
preinfarction angina and size of the initial MaR.112	An	accurate	quantification	of	MaR	and	
infarct	size	is	a	prerequisite	when	evaluating	treatment	efficacy	in	studies	aimed	at	limiting	
reperfusion injury. 113 Both the extent of the myocardium made ischemic by the coronary 
Figure 4. Schematic representation of the different pathways. The binding of tumor 
necrosis factor (TNF-α) to its TNF receptor-2, and the subsequent activation of signal 
transducer and activator of transcriptin-3 (STAT-3), confers cardioprotection via the 
survivor activating factor enhancement (SAFE) pathway. The SAFE pathway and the 
reperfusion injury salvage kinases (RISK) pathway may both confer protection through 
the mitochondrial permeability transition pore (mPTP). Activation of sphingosine kinase 
generates sphingosine-1-phosphate, which seems to recruit other components of both the 
RISK and SAFE pathways. Adapted from Lacerda et al.99 
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artery	 occlusion	 and	 the	 amount	 of	 finally	 damaged	myocardium,	 the	 infarct,	 are	 crucial	
when expressing the relationship between these two parameters and thereby the proportion 
of	salvaged	myocardial	tissue.	As	depicted	in	Figure	5,	myocardial	salvage	is	defined	as	the	
jeopardized MaR minus the actual infarct size. Relating these two entities to one another 
enhances the possibility to identify small cardioprotective effects and to compare large and 
small infarctions within the same study population, thereby permitting smaller sample sizes 
while maintaining enough power for the investigation.114 The following section will describe 
the techniques used for determination of MaR and infarct size in this thesis.
Cardiac imaging techniques
Left ventriculography
Abnormal wall motion can be assessed by left ventriculography allowing highly reproducible 
measurements of LVEF and the absolute LV volume. It is routinely used in the catheter 
laboratory	when	determining	left	ventricular	function	and	in	grading	valvular	insufficiency.	
Left ventriculography can be performed just prior to revascularization of STEMI patients 
with very little time delay in order to determine MaR. Field et al115	first	described	the	method	
for estimation of the extent of circumferential wall motion abnormality. Other angiographic 
techniques for determination of MaR are the Bypass Angioplasty Revascularization 
Investigation (BARI) and the Alberta Provincial Project for Outcome Assessment in 
Coronary Heart Disease (APPROACH) scores.116 The BARI and APPROACH scores are 
calculated by grading all ending arteries. The MaR is then calculated as a percentage of the 
LV by dividing summed scores of a jeopardized area by the total score of the entire LV. The 
APPROACH score, which takes coronary dominance into account, has been validated against 
CMR117. Limitations with left ventriculography include the exposure to excessive amounts of 
contrast which can cause kidney failure, allergic reactions and the use of additional ionizing 
radiation.
Myocardial perfusion SPECT
Noninvasive radionuclide cardiac imaging started in the 1970s. Since then, there have been 
major advances in the ability to image cardiac physiology and pathophysiology, including that 
of	myocardial	blod	flow,	metabolism	and	ventricular	function.118 
Figure 5. Myocardial salvage. Corresponding left ventricular short axis views from a patient 
with inferior STEMI. Myocardium at risk (MaR) determined by contrast enhanced steady-
state free precession (CE-SSFP) at end-diastole (left), infarct size image (middle). The 
infarcted area is superimposed on MaR (right) and the pink area is the myocardial salvage. 
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Myocardial perfusion SPECT studies perfusion of the myocardium by means of radioactive 
tracers and tomographic imaging of the heart with a gamma camera. Modern tracers like 
technetium (99m Tc) labeled sestamibi and tetrofosmin have better distribution patterns than 
the previously used thallium, thanks to to a high extraction rate from blood, no re-distribution 
to the blood, a relatively high uptake into the cardiomyocytes and a moderate half-time decay. 
This makes it possible to inject the isotope before opening the occluded coronary artery and 
the implication is that MaR can be determined during a time window of four to six hours 
following reperfusion. After acquisition, the data is reconstructed to enable assessment of LV 
volumes, myocardial perfusion, MaR and, if ECG-gated, myocardial function. Myocardial 
SPECT is considered to be the reference standard for determining MaR. This technique 
was until recently also the reference standard for determining myocardial infarct size.119, 120 
During the last two decades, multiple studies have validated the clinical use of SPECT for 
measurement of infarct size and MaR.121-124 SPECT, which has few contraindications, has been 
used in several multicenter studies using infarct size estimation as an end point.72, 85-87, 125  
Problems related to SPECT are the limiting image resolution (subendocardial necrosis can 
be missed), problems with attenuation artifacts, the use of high doses of ionizing radiation 
and the short half-life of the nuclear tracers making the technique impractical in an acute 
setting.
Cardiac magnetic resonance imaging
The use of CMR, which is a non-invasive and non-ionizing technique, has grown considerably 
in	recent	years	and	is	now	firmly	established	in	clinical	practice	and	research.	CMR	is	reliable,	
relatively easy to use, produces superb image quality and has excellent reproducibility which 
makes it well suited for studies of cardioprotection. 
Basic physics 
Hydrogen is present everywhere in the human body in the form of water and has good 
sensitivity to magnetic resonance, which is the basis when producing images with a high 
signal-to-noise ratio. The hydrogen nuclei behave like small magnets aligning to an external 
magnetic	 field.	When	 exposed	 to	 a	 field	 of	 1.5	 Tesla,	 the	 nuclei	 precess	 at	 a	 resonance	
frequency of 63 MHz, which is within the radiowave range. A radiowave pulse can excite 
a region of the body at this frequency causing the hydrogen nuclei to rotate away from the 
direction	of	 the	main	magnetic	field	 in	 a	 coordinated	way,	 thereby	causing	another	 small	
magnetisation	field.	After	the	pulse	is	switched	off,	the	new	small	magnetisation	field	decays	
to its former position and energy is transmitted as a radio signal. This signal is transformed 
into a radiowave echo and can be formed into an image using a receiver antenna and computer 
processing. The contrast between different tissues in the image depends on the delay between 
excitation, the read-out signal (echo time, TE) and the time between repetitive radiowave 
excitations (repetition time, TR). 
CMR	 uses	 complex	 sequences	 to	 characterise	 different	 tissues	 based	 on	 specific	 nuclear	
properties including T1 and T2. The longitudinal relaxation, commenly referred to as T1 
relaxation, is responsible for the recovery of the protons to its original magnetization value 
in	equilibrium.	T1	is	a	rate	constant	defined	as	the	time	it	takes	for	the	hydrogen	nuclei	to	
regain 63 % of the original magnetisation. T1-weighted images can separate tissues if they 
differ in intrinsic or pathological T1. Such images are commonly used to visualize the tissue 
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distribution of gadolinium contrast. The gadolinium-based contrast agent is paramagnetic 
and increases tissue contrast by shortening T1-relaxation in tissue containing gadolinium. It 
distributes into the extracellular space and the concentration is proportional to the relative 
amount of extracellular space.126 In acute myocardial infarctions, the extracellular space is 
increased due to ruptured myocytes and edema. The transverse relaxation, commonly referred 
to	as	T2,	describes	how	long	protons	remain	in-phase	after	being	flipped	perpendicular	to	
the	main	magnetic	field.	T2	is	a	rate	constant	defined	as	the	time	it	takes	for	the	hydrogen	
nuclei	to	decrease	to	37	%	of	the	initial	value.	In	general	T2-weighted	images	show	fluids	
with bright signal intensity while solid tissues, like the myocardium. have an intermediate 
intensity. When imaged with T2-weighted sequences the MaR, because of its higher water 
content, appears slightly brighter than the remote myocardium. 
The major components of a modern CMR system consist of hard- and software: a 
superconducted	magnet	that	produces	a	highly	homogeneous	and	stable	static	magnetic	field;	
the	gradient	amplifiers	and	coils	within	the	bore	of	the	magnet	that	generates	the	excitation	
pulses; and a radiofrequency antenna that receives the signal from the patient. An advanced 
computer controls all these components and performs a Fourier transformation of the radio 
signal	to	generate	the	final	images.	
CMR sequences
There is a large variety of CMR sequences. The majority of imaging is performed using 
two basic sequences known as spin- and gradient-echo. Spin-echo sequences are usually 
referred to as “black-blood” and gradient sequences as “bright-blood”. Spin-echo sequences 
are routinely used for anatomical imaging and gradient-echo sequences are for functional 
assessment through cine acquisitions. The most commonly used prepulse is inversion recovery 
(IR), which gives a strong T1-weighting and is valuable when imaging infarcted tissue. 
CMR	has	high	spatial	resolution	to	discriminate	subendocardial	from	transmural	fibrosis	and	
allows detection of micro-infarctions.127 CMR has a higher sensitivity for MI than SPECT 
and PET128 and can better differentiate viable from nonviable myocardium.129 The correlation 
between	late	gadolinium	enhancement	(LGE)	and	fibrosis	has	been	extensively	validated	and	
is	currently	the	standard	reference	for	quantification	of	MI	size.	129-132 LGE imaging has been 
validated in multicenter clinical trials.133 
Different CMR sequences have been applied to depict MaR and there is still no general 
consensus on which one to use. Several sequences characterise MaR by determining the 
myocardial edema retrospectively within two to seven days after the index ischemia.134-138 
MaR using T2-weighted sequences are the most extensively studied. Higgins et al were the 
first	to	quantify	myocardial	T2	in	acute	MI	in	dogs	in	1983.139 They reported changes in both T2 
and T1 in infarcted myocardium. Two decades later, it was shown that different T2-weighted 
images could depict MaR several days after the ischemic event and also differentiated acute 
from chronic myocardial damage. 134-138 In 2009, Carlsson et al140 validated the T2-weighted 
sequence against SPECT and the method was subsequently used to demonstrate the rate of 
infarct evolution in man, without confounders.141 More recently, the possibility of quantifying 
myocardial T2 and T1 in normal and ischemic myocardium has been demonstrated. This 
may solve the problems related to subtle differences in signal intensity between normal and 
edematous myocardium.142, 143 Another CMR method to estimate MaR is the “endocardial 
surface area” which relies on the wave front of myocardial injury that occurs in acute MI.117 
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MaR is estimated from the endocardial extent of the infarction and calculated in relation to the 
whole left ventricle endocardial surface. Ubachs et al recently reported that the endocardial 
extent of LGE underestimates the MaR and consequently myocardial salvage.144
The limitations of CMR in cardioprotective studies have to be recognised. While LGE 
is	 accepted	 as	 the	 reference	 for	 the	quantification	of	 the	final	 infarct	 size,	 the	 experience	
with different sequences regarding MaR is considerably smaller. Other limitations include 
problems	with	artifacts,	sequences	that	are	often	vendor-specific	and	not	available	for	all	CMR	
centers and the lack of extensive validation of some sequences. Claustrophobia, high cost and 
pacemakers/defibrillators	not	compatible	with	CMR	may	also	limit	the	use	of	CMR.		
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AIMS
The overall aim of this thesis was to investigate the effects of postconditioning on infarct size 
and	to	improve	the	methodology	for	the	quantification	of	myocardial	protection	in	patients	
with STEMI. 
The	specific	aims	were	to:
I. Evaluate the short-term effect of postconditioning on infarct size in patients with 
STEMI
II. Evaluate the long-term effect of postconditioning in patients with STEMI
 
III.	 Develop	and	validate	a	method	for	the	quantification	of	MaR	using	contrast	enhanced	
CMR one week after the infarction
IV. Explore the relationship between contrast enhanced CMR and T2-weighted edema 
imaging	for	the	quantification	of	MaR	
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MATERIAL AND METHODS
The protocols and procedures were approved by the local ethic committees for human 
research at Karolinska Institutet and the University of Lund, Sweden. The studies were 
performed according to the declaration of Helsinki and good clinical practice.145 Written 
informed consent was given by all patients.
Study populations
Study I and II
Between April 2007 and March 2009, a total of 795 patients were referred to the coronary 
care unit of Karolinska University Hospital, Solna, for a primary PCI due to STEMI. As can 
be seen in Figure 6, 89 patients were randomized and 76 completed the study protocol in 
study I and 68 patients completed the long-term follow-up in study II. 
Inclusion	 criteria	 were	 chest	 pain	 ≥30	 min	 and	 ≤6	 h	 in	 combination	 with	 ST-segment	
elevation	≥0.1	mV	(≥0.2	mV	in	V1-V3)	in	two	contiguous	ECG	leads	or	left	bundle	branch	
block	and	a	thrombolysis	in	myocardial	infarction	(TIMI)	grade	0	flow	in	the	infarct-related	
artery.146 Exclusion criteria were previous MI, previous CABG, cardiogenic shock, cardiac 
arrest, renal impairment (serum creatinine >150 mmol/l), ongoing treatment with metformin, 
contraindication	for	CMR,	persistent	atrial	fibrillation	and	any	condition	that	was	considered	
to interfere with the possibility for the patient to complete the study protocol.  
Eligible
n = 795
Randomized 
n = 89
Standard PCI 
n = 45
Postconditioning
n = 44
Control group
Study I
n = 38
Postconditioning
Study I
n = 38
Control group
Study II
n = 35
Postconditioning
Study II
n = 33
Excluded 7
Unwillingness 3
Poor image quality 3
Sudden death 1
Excluded 3
Unwillingness 3
Excluded 6
Unwillingness 3
Protocol violation 2
Poor image quality 1
Excluded 5
Unwillingness 2
Misc 2
CABG 1
Inclusion criteria not met or 
fulfilling exclusion criteria
n = 706
Figure 6. Flow chart of patient recruitment in Studies I and II. 
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The main reason for loss to follow-up in Studies I and II was unwillingness to complete the 
protocol and poor image quality. One patient in the control group died suddenly. Recurrent 
MI did not occur in any of the two groups during follow-up.
Study III
Study	III	comprised	16	consecutive	patients	(age:	64	±	8	years;	12	males)	with	a	first-time	
STEMI	fulfilling	the	inclusion	and	exclusion	criteria	as	described	for	Studies	I	and	II.	They	
were admitted for primary PCI during the period February 2007 to December 2008 at times 
when myocardial perfusion scintigraphy was accessible. Twelve patients were included at the 
Karolinska University Hospital Solna and four at the Lund University Hospital. The culprit 
lesion was located in the right coronary artery (RCA) in 13 patients, the LAD in two and the 
LCx in one. There were no severe adverse events, including reinfarctions, prior to the CMR 
investigation. 
Study IV
Twenty-one patients (age 59 ± 10 years; 17 males) presenting at Lund University Hospital with 
a	first-time	acute	STEMI,	due	to	an	occluded	coronary	artery	confirmed	with	angiography,	
were prospectively included in study IV. All patients were treated with primary PCI with 
coronary	 stenting,	 resulting	 in	TIMI	grade	3	flow	 in	 the	culprit	 artery.	The	RCA	was	 the	
culprit vessel in 12 patients and the LAD in six patients. Furthermore, two patients presented 
with an occlusion of the LCx artery and one patient had a left main occlusion. 
Study design
Studies I and II
The study was conducted as a prospective randomized open study with blinded evaluation. 
All patients received aspirin, clopidogrel and enoxaparin. A GPIIb/IIIa inhibitor was given 
according to the choice of the PCI operator. A coronary angiography was performed to 
confirm	TIMI	0	flow	in	the	infarct-related	artery.	In	order	to	determine	MaR,	a	biplane	left	
ventriculography was performed before revascularization.
Following these procedures, the patients were randomized to primary PCI only or PCI 
combined	with	postconditioning	performed	by	reinflating	the	balloon	at	the	same	location	to	
a pressure of 2-4 atmospheres for 60 seconds, starting 60 seconds after the initial reperfusion 
(Figure 7). Postconditioning was performed with the same balloon catheter as the one used 
for	the	initial	inflation.	The	PCI	intervention	was	completed	through	a	coronary	angiogram	to	
determine	the	final	TIMI	flow.	Collateral	flow	to	the	infarct	zone	was	assessed	on	the	initial	
angiogram before PCI and graded on a scale of zero to three.147
Blood	sampling	was	performed	at	admission	and	every	four	hours	during	the	first	24	hours	
and then every six hours until 48 hours after reperfusion. Both peak values and AUC of 
cardiac biomarkers were determined. A standard CMR was scheduled one week after the 
onset of symptoms (Study I) as well as at three and 12 months (Study II) for determination of 
cardiac volumes, infarct size and microvascular obstruction.  
Study III
The patients were consecutively recruited for Study III received an intravenous injection of 
99 mTc-labeled tetrofosmin or sestamibi prior to opening of the occluded vessel. All patients 
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received oral antiplatelet therapy with aspirin, clopidogrel and intravenous infusion of a GPIIb/
IIIa inhibitor in connection with the PCI procedure. Myocardial perfusion SPECT imaging 
was performed within four hours, to visualize and quantify MaR. A CMR examination was 
performed one week after the onset of symptoms.
Study IV
The patients treated with primary PCI due to STEMI were consecutively recruited and 
enrolled at Lund University Hospital. All patients received oral antiplatelet therapy with 
aspirin, clopidogrel and intravenous infusion of a GPIIb/IIIa inhibitor in connection with the 
PCI procedure. A CMR examination was performed one week after the onset of symptoms.
Methods
Angiographic determination of MaR (Studies I and II)   
MaR	 was	 quantified	 by	 measuring	 the	 circumferential	 extent	 of	 abnormally	 contracting	
segments. Left ventriculography (30º right anterior oblique, 60º left anterior oblique) was 
performed immediately before coronary angioplasty during infusion of 40 ml of iodine 
contrast. An x-ray digital imaging software system (Integris HM 3000, Philips, The 
Netherlands) was used for determining the global and regional LV function. Global ejection 
Figure 7. The protocol used in Studies I and II. Patients with STEMI were randomized 
either to a control group (n=45) with standard PCI (primary coronary intervention) or to an 
intervention group (n=44) in which the PCI was followed by postconditioning in four cycles 
of reperfusion for 60 seconds followed by ischemia for 60 seconds. Cardiac biomarkers 
were measured for 48 hours after admission. Cardiovascular magnetic resonance (CMR) 
was scheduled at one week (n=38/38), three and 12 months (n=35/33) after the PCI. Left 
ventricular (LV) angiography for estimation of myocardium at risk (MaR) was performed 
prior to PCI. TnT (Troponin T). 
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fraction was calculated using the area-length method. Centerline chord motion analysis was 
used to quantitatively assess regional LV function. In this technique, endocardial motion is 
measured along 100 chords constructed perpendicular to a centerline. The motion of each 
chord was normalized by the end-diastolic circumference to yield a fractional shortening. 
This value was converted into units of SD from the normal mean motion of each chord 
as derived from a normal reference population. Wall motion and abnormally contracting 
segments were analyzed in the distribution territory of the LAD (10 to 66 chords) in patients 
with anterior infarctions, and in the distribution territory of the RCA or LCx (51 to 80 chords) 
in	patients	with	inferior	infarctions.	Abnormal	wall	motion	extent	was	defined	as	the	number	
of chords displaying hypokinetic motion (<1 SD) expressed as a percentage of the LV.115, 148 
These measurements were performed by two experienced investigators unaware of the group 
to which each patient belonged.
Cardiovascular Magnetic Resonance (Studies I-IV)
A standard clinical CMR protocol, except for the time of administration of contrast, was 
scheduled to be performed one week, three and 12 months after the onset of symptoms. 
Timing was chosen at one week to avoid the early infarct phase during which a rapid decrease 
in infarct size has been reported.149 Two different 1.5 T CMR systems (Signa Excite Twin-
Speed, General Electric Healthcare, Waukesha, WI, USA or Philips Intera CV, Best, The 
Nederlands) were used in Studies III and IV. In Study I and II only the GE camera was used. 
Eight-	and	five-channel	cardiac-coil	was	used	and	all	patients	were	 in	 the	supine	position	
with vector-ECG monitoring. A bolus of gadolinium contrast agent 0.2 mmol/kg bodyweight 
(Omniscan, GE Healthcare, Norway or Magnevist, Bayer Pharma, Berlin, Germany) was 
given intravenously just before positioning the patient in the scanner. The image protocol 
included scout images, localization of the short axis and then covering the whole LV with 
retrospectively gated steady-state free precession (SSFP) cines referred to as contrast-
enhanced (CE-SSFP) images in Studies III and IV. The following typical parameters on GE-
scanner	was	used;	SSFP	(TE	1.58	ms,	TR	3.61	ms,	flip	angle	60	degrees,	25	phases,	8	mm	
slice, no gap, matrix 226 × 226). LGE images were acquired 15-20 minutes after contrast 
injection using an inversion recovery gradient echo sequence (TE 3.3 ms, TR 7.0 ms, TI 180-
250 ms to null the myocardium, 8 mm slice, no gap, matrix 256 × 192) and the same slice 
orientation as cine SSFP images. Typical parameters on the Philips scanner were; SSFP (TE 
1.4	ms,	TR	2.8	ms,	flip	angle	60º,	30	phases,	8	mm	slice,	matrix	160	×	141).	LGE	images	
were acquired 15-20 minutes after contrast injection using inversion recovery gradient echo 
sequence (TE 1.14 ms, TR, 3.8 ms, TI 180-250 ms, 8 mm slice, no gap, matrix 240 × 180). 
Cardiac triggering was set for diastole to reduce motion artifacts. Each slice was obtained 
during end-expiratory breath holding. Two-, three- and four-chamber views were also 
obtained	to	confirm	the	findings.	An	additional	T2-weighted	triple	inversion	turbo	spin-echo	
sequence (T2-STIR) was added in study IV before contrast bolus was given to depict the 
MaR. Imaging parameters for the T2-weighted sequence were: echo time, 100 ms; repetition 
time, 2 heart beats; number of averages, 2; inversion time, 180 ms; image resolution, 1.5 
x 1.5 x 8 mm; slice gap, 0 mm. No parallel imaging was performed to minimize signal 
inhomogeneities, due to differences in coil sensitivity. 
Image analysis
All CMR images were analyzed off-line using freely available segmentation software 
(Segment v1.7 – v1.8 http://segment.heiberg.se/).150 In the short-axis stack end-diastolic and 
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end-systolic volumes were measured in the phase with the largest and smallest LV volumes 
respectively. LVEF, stroke volume and LV mass were calculated on cine SSFP sequences 
using manual delineation of the endocardial and epicardial borders, including papillary 
muscles and trabeculations when contiguous with the left ventricle. For correct LV volumes 
and mass estimations the basal slices were examined in different cine projections. LV mass 
was calculated by multiplying the myocardial volume by the density of myocardial tissue 
(1.05 g/ml). All volumes were indexed to body surface area.
The MaR derived from T2-weighted imaging was assessed by tracing endocardial and 
epicardial borders of the LV in all short-axis slices, followed by manual delineation of the 
hyperintense regions. The papillary muscles were excluded from the myocardium. The MaR 
was	 then	defined	 as	 the	 total	 amount	of	 hyperintense	myocardium	 in	 all	 short-axis	 slices	
and expressed as a percentage of LVmass. If present, hypointense myocardium within the 
area of increased signal intensity (microvascular obstruction) was included in the MaR. The 
contrast ratio for the T2-weighted images was determined for each patient as the mean signal 
intensity in the MaR divided by the mean signal intensity in remote myocardium. The MaR 
derived from CE-SSFP was also assessed by tracing endocardial and epicardial borders of 
the left ventricle in all short-axis slices in end-diastole and end-systole, followed by manual 
delineation of the hyperintense regions in both end-diastole and end-systole, by two observers 
blinded to LGE images. The values of MaR in end-diastole and end-systole were averaged 
and expressed as a percentage of the LV mass. The contrast ratio for the CE-SSFP images 
was determined for each patient as the mean signal intensity in the MaR divided by the mean 
signal intensity in remote myocardium. 
The	 infarcted	myocardium	was	automatically	quantified	 from	the	short-axis	LGE	images.	
The endocardial and epicardial borders were traced manually with exclusion of the papillary 
muscles.	The	LGE	myocardium	was	then	defined	using	a	computer	algorithm	that	takes	into	
consideration partial volume effects within the infarcted region.151 Manual adjustments were 
made when the computer algorithm was obviously wrong. If present, a hypointense signal 
within the area of LGE (microvascular obstruction) was included in the analysis as 100 % 
infarction. Myocardial infarct size was expressed both as a percentage of the LV and as a 
percentage	of	MaR.	The	myocardial	 salvage	 index	was	defined	as	100	x	 ([MaR	–	 infarct	
size]/MaR), where MaR was assessed using both T2-weighted imaging and CE-SSFP.
In study II, change in LV sphericity index was used for detection of cavity remodeling.152 
The major axis was manually measured in an end-diastolic four-chamber view starting at 
the mitral annulus and ending at the apical endocardial border. The radius was used for 
calculating the sphere volume. End-diastolic LV volume was divided by the sphere volume 
creating a sphericity index for every patient.
SPECT (Study III)
Myocardial perfusion SPECT was used as reference standard for quantifying MaR. Prior to 
opening of the occluded vessel, the patients received a body weight-adjusted (350-700 MBq) 
intravenous injection of 99 mTc-labeled tetrofosmin (Amersham Health, Buckinghamshire, 
UK) or sestamibi (MIBI, Cardio-lite, Bristol Myers Squibb, USA). Myocardial perfusion 
SPECT imaging was performed within four hours to visualize and quantify MaR using 
either of two dual-head cameras: GE camera (Ventri, GE Healthcare, USA) or Sopha camera 
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(DSTXL; Sopha Medical Vision, Bue Cedex, France). The patients were placed in the supine 
position and imaged in steps of 5.6 degrees using a 64 × 64 matrix, with a typical pixel size 
of 5 × 5 mm and a slice thickness of 5 mm. The reconstructed voxel size was 3 × 3 × 3 mm 
(Sopha) or 6.4 × 6.4 × 6.4 mm (GE). Image acquisition time was approximately 15 minutes. 
Iterative reconstruction using maximum likelihood expectation maximization was performed 
with	a	low-resolution	Butterworth	filter	and	a	cut-off	frequency	set	to	0.5	of	Nyquist	and	an	
order of 5.0. No attenuation or scatter correction was applied and short-axis images were 
reconstructed semi-automatically on the respective workstation for each camera.
Image analysis
Analysis of myocardial perfusion SPECT defect for MaR was performed off-line using the 
program	mentioned	above.	The	automatic	segmentation	finds	the	centerline	through	the	LV	
wall	and	identifies	the	endo-	and	epicardium	based	on	individually	estimated	wall	thickness	
and signal intensity values within the image.153 Manual adjustment of the automatic delineation 
was	sometimes	required	in	the	left	ventricular	outflow	region	and	basalt	slices.	The	perfusion	
defect was determined using an automated algorithm that considers myocardium with <55% 
of normal as being ischemic.154	MaR	was	quantified	as	percentage	of	the	LV	mass.
Blood analysis
In Study I, Troponin T was analyzed with an immunoassay (Modular Analytics E-module, 
Roche Diagnostics) and CKMB (creatine kinase, myocardial bound) with a chemiluminescence 
technique (UniCel DxI 800, Beckman Coulter AB). Sampling was performed at admission 
and	every	four	hours	during	the	first	24	hours	after	reperfusion	and	then	every	six	hours	until	
48 hours. Both peak values and AUC were determined. 
Statistics
The primary endpoint of Study I was infarct size after one week, expressed as percentage 
of MaR. Secondary endpoints were global left ventricular function and release of cardiac 
biomarkers during the 48 hours following the coronary intervention. Based on an expected 
reduction in infarct size of 20 % and SD of 30 %, 36 patients were needed in each group to 
achieve p<0.05 with a power of 80 % and a two-tailed test. To compensate for patient dropout, 
a total number of 90 patients was planned to be recruited. Computer-generated randomization 
in	blocks	of	eight	was	performed	following	stratification	for	LAD	and	non-LAD	occlusions.	
All data were presented as medians and 25th, 75th percentiles (Studies I and II). The Mann-
Whitney U test was used to test for differences in infarct size and cardiac biomarkers between 
groups. Fisher’s exact test was used to test for differences between dichotomized variables. 
Linear regression was used for comparing infarct size in relation to the MaR between groups, 
and regression analysis was performed with four residuals looking at the best equation.
In Study II the same statistical methods were used for comparing groups at three and 12 
months, in addition to Wilcoxon sign rank test with Bonferroni correction for multiple 
testing, used for longitudinal follow-up on CMR measurements. In Studies III and IV, data 
were expressed as mean±SD. Wilcoxon Mann-Whitney Rank Sum test was used to test for 
differences between groups (SPECT and CE-SSFP). Wilcoxon Sign Rank test was used to test 
the relative signal enhancement in contrast-enhanced regions on CE-SSFP images compared 
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with remote myocardium. Pearson’s correlation was used to determine the relationship 
between T2-weighted imaging and CE-SSFP with regard to both MaR and the myocardial 
salvage index. Bland-Altman plots were constructed for comparing intra- and interobserver 
variability and calculated as the SD of the difference between two calculations divided by 
the average of the two observers. Statistical analysis was performed using GraphPad Prism 
version 5.00 (GraphPad Software, San Diego, California, USA) and SPSS version 17.0 
software package (Chicago, Illinois, USA).
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RESULTS
Study I: Short-term effects of postconditioning in patients with STEMI 
Clinical characteristics and angiographic details from the patients are shown in Tables 1 and 
2. As can be seen, the two study groups were well balanced. 
Table 1. Patient Characteristics in the Control and Postconditioning groups
Variables Control Group Postconditioning 
Group
p
Risk factors
Age, years (range) 62 (42-85) 63 (37-87) 0.52
Male sex, n (%) 34 (89) 31 (82) 0.52
Body mass index, kg/m2 27 (25, 29) 27 (25, 31) 0.56
Ischemia time, minutes 185 (141, 259) 165 (137, 223) 0.40
Current smokers, n (%) 11 (29) 10 (26) 1.0
Dyslipidemia*, n (%) 21(62) 27(77) 0.80
Hypertension, n (%) 11(29) 6(16) 0.27
Previous angina, n (%) 3 (8) 6 (16) 0.49
Diabetes**, n (%) 12 (36) 17 (47) 0.47
Treatment on admission
   aspirin, n (%) 3 (8) 2 (5) 1.0
   beta-blockers, n (%) 4 (11) 1 (3) 0.36
   ACE/ARB, n (%) 5 (13) 2 (5) 0.43
   statins, n (%) 3 (8) 3 (8) 1.0
Treatment during angioplasty
   opioids, n (%) 29 (76) 31 (82) 0.78
   aspirin, n (%) 38 (100) 36 (95) 0.49
   clopidogrel, n (%) 37 (97) 36 (95) 1.0
   glycoprotein inhibitors, n (%) 30 (79) 30 (79) 1.0
Treatment at discharge
   aspirin, n (%) 38 (100) 37 (97) 1.0
   clopidogrel, n (%) 38 (100) 38 (100) 1.0
   beta-blockers, n (%) 37 (97) 38 (100) 1.0
   ACE/ARB, n (%) 20 (53) 23 (61) 0.64
   statins, n (%) 37 (97) 37 (97) 1.0
Data are presented as median and quartiles for continuous variables except age which is median and 
range, or number of patients and percentage for dichotomous variables. 
ACE = angiotensin converting enzyme inhibitor, ARB = angiotensin receptor blocker.
*n=34 (control), 35 (postconditioning), **n=33 (control), 36 (postconditioning)
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Infarct size and left ventricular ejection fraction
The	 postconditioning	 protocol	 with	 inflation	 and	 deflation	 of	 the	 PCI	 balloon	 was	 well	
tolerated in all patients and no technical problems occurred during the procedure. Infarct 
size,	presented	as	a	percentage	of	MaR	(Figure	8),	did	not	differ	significantly	between	the	
two groups: control patients 44 % (30, 56) and postconditioning patients 47 % (23, 63). In 
the	multiple	regression	analysis,	infarct	size	was	significantly	related	to	postconditioning	and	
MaR (p=0.001) but not to age, sex, ischemic time or smoking habits. The regression analysis 
in	which	the	final	infarct	size	was	related	to	MaR	showed	a	significant	difference	in	slope	of	
the regression lines between the postconditioning group and the control group (Figure 9). A 
detailed analysis was therefore performed in patients with MaR in the upper quartile. Final 
infarct size in patients in this subgroup (n=19; Figure 10) was 54 % (50, 68) among those 
belonging to the control group and 33 % (21, 57) in postconditioned patients (p=0.03). There 
were	no	significant	differences	between	patients	belonging	to	the	lower	quartiles.	
Median LVEF after one week did not differ between the control and postconditioned patients: 
controls = 50 % (40, 55) and postconditioned = 50 % (41, 54). In patients with large MaR, 
there	was	a	significant	difference	in	the	slopes	of	the	regression	lines,	with	a	higher	LVEF	in	
patients in the postconditioning compared with those in the control group (Figure 11). 
Intra- and interobserver variation between two blinded readers for infarct size measurement 
(n=20) was 0.0±3.5 % and 0.7±1.1 % (difference and SD), respectively.
Table 2. Angiographic Data
Variable Control Group Postconditioning 
Group
p
Infarct related artery
   LAD, n (%) 14 (37) 14 (37) 1.0
   LCx, (%) 1 (3) 4 (11) 0.36
   RCA, n (%) 23 (61) 20 (53) 0.64
Collateral	flow	grade	2	or	3,	n	(%) 8 (21) 6 (16) 0.77
Number of vessels
   one-vessel disease 25 (66) 23 (61) 0.81
   two-vessel disease 11 (29) 11 (29) 1.0
   three-vessel disease 2 (5) 4 (11) 0.67
Abnormally contracting segments (%) 23 (15, 34) 30 (19, 40) 0.19
Direct stenting, n (%) 2 (5) 0 (0) 0.49
Bare metal stent, n (%) 38 (100) 37 (97) 1.0
TIMI	flow	grade	3	after	PCI,	n	(%) 35 (92) 34 (89) 1.0
Data are presented as median and quartiles for continuous variables except age which is median and 
range, or number of patients and percentage for dichotomous variables. 
LAD	=	left	anterior	descending	coronary	artery;	RCA	=	right	coronary	artery;	LCx	=	left	circumflex	
coronary artery; TIMI = Thrombolysis In Myocardial Infarction; PCI = percutaneous coronary 
intervention.
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Cardiac biomarkers
In the overall study population there were no differences troponin T and CKMB (AUC or 
peak values) between the control and postconditioning groups. AUC for troponin T was 
147 (80, 269) and 165 (95, 279) in the control and postconditioning groups while AUC for 
CKMB was 3890 (2388, 6264) and 4175 (2406, 6060) respectively. The regression analysis 
in which troponin T was related to the MaR showed a trend favoring the postconditioning 
group (p=0.09). There was no difference in troponin T release between the groups when 
comparing the upper quartile of MaR. When AUC for CKMB and troponin T was compared 
with both MaR and infarct size measured with CMR, a stronger correlation was seen with 
infarct size than with MaR (data not shown).   
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Figure 8. Infarct size in relation to the 
myocardium at risk (MaR) one week 
after admission. Infarct size did not differ 
significantly between patients in the control 
and postconditioning groups.
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Figure 9. Infarct size plotted against myo-
cardium at risk (MaR) for the overall study 
population. There are significant differences 
between the slopes of the regression lines 
between patients in the control (○)	and post-
conditioning (●) groups. LV, left ventricular.
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Figure 10. Infarct size in patients with 
myocardium at risk (MaR) in the upper 
quartile one week after admission. A 
significantly smaller infarct size can be 
seen in the postconditioning group.
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Figure 11. Left ventricular ejection fraction 
(LVEF) determined suing CMR after one 
week and plotted against myocardium at 
risk (MaR). There is a significant difference 
between the slopes of the regression line 
between patients in the control (○) and 
postconditioning (●) groups.
p=0.01
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Study II: Long-term follow-up of postconditioning in patients with STEMI 
Infarct size and LVEF
Median infarct size, expressed as a percentage of MaR, at three and 12 months did not differ 
between the control and postconditioning groups for the entire study population (Figure 12). 
The	slope	of	the	regression	lines	for	the	final	infarct	size	in	relation	to	MaR	did,	however,	
differ	 significantly	 between	 the	 two	 groups,	 an	 observation	 that	was	 consistent	 over	 time	
(Figure 13). In the upper quartile of MaR (n=17) patients randomized to postconditioning had 
significantly	smaller	infarct	sizes	than	the	control	patients	at	12	months	and	a	trend	in	the	same	
direction was seen at three months (Figure 14). Median LVEF for the whole study population 
did not differ between the control and postconditioning groups. The slope of the regression 
lines	describing	LVEF	in	relation	to	MaR	differed	significantly	between	the	two	groups	at	12	
months.	In	the	group	of	patients	in	the	upper	quartile	of	MaR,	LVEF	was	significantly	higher	
in the postconditioning group than in the control group both at three and 12 months (Figure 
15).	Adverse	LV	remodeling	(defined	as	a	consistent	increase	in	ESV	>15	%)	occurred	in	nine	
patients equally distributed between the two groups. End-diastole LV sphericity index for the 
entire study population did not differ between or within groups over time.
The intra- and interobserver variation between two blinded readers for infarct size measurement 
(n=18) was 0.2±1.0 % and 0.1±1.3 % and for LV mass (n=12) was -0.8±7.0 g and -0.4±6.8 g 
(mean difference ± SD), respectively.
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Figure 12. Infarct size in relation to myocardium at risk (MaR) for the overall study population 
at (A) 3 and (B) 12 months in the control group and the postconditioning group.
Figure 13. Infarct size (expressed in relation to left ventricular mass) plotted against 
myocardium at risk (MaR) for the overall study population at (A) 3 and (B) 12 months in 
patients belonging to the control (○)	and postconditioning (●) groups. Significant differences 
between the slopes of the regression lines of the two groups are indicated.
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Study III: Validation of contrast-enhancement SSFP
Myocardium at risk
MaR,	defined	as	the	non-perfused	myocardial	volume	on	SPECT,	ranged	from	11	to	51	%	
(mean 27 ± 10 %) of the LV wall volume. The CE-SSFP, calculated as the mean values 
obtained at end-diastole and end-systole, ranged from 17 to 47 % (mean 27 ± 7 %) of the 
LV wall volume. There was a good correlation (Figure 16) between MaR determined from 
CE-SSFP and that determined with SPECT (r2 = 0.78, p < 0.001). The difference between 
CE-SSFP and MaR on SPECT was 0.5 ± 5.1 % (p = 0.60). The location of the enhanced 
region on SSFP cines always agreed with MaR on myocardial perfusion SPECT images. 
Two typical examples of MaR and infarct area in the RCA and LAD regions are shown in 
Figures 17 and 18. The signal intensity ratio between regions of gadolinium-enhanced and 
remote myocardium was 1.42 ± 0.25 (p < 0.001). The interobserver variability for CE-SSFP 
between two readers was 1.6 ± 3.7 %. Infarct size determined using CMR ranged from 1 to 
30 % (mean 9 ± 7 %) of LV wall volume and mean transmurality ranged from 26 to 52 %. 
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Figure 14. Infarct size in patients within the upper quartile of myocardium at risk (MaR) at 
(A) 3 and (B) 12 months in the control group and the postconditioning group. 
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Figure 15. Left ventricular ejection fraction (LVEF) in patients within the upper quartile 
of myocardium at risk (MaR) at (A) 3 and (B) 12 months in the control group and the 
postconditioning (PostC) group.
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Figure 16. Agreement between MaR determined using CMR and SPECT. Panel A: Scatter 
plot showing MaR one week after reperfusion determined using contrast-enhanced SSFP 
(CE-SSFP) versus MaR as it was before reperfusion determined using myocardial perfusion 
SPECT together with line of identity. Panel B: Bland-Altman plot showing the agreement 
between MaR determined using myocardial perfusion SPECT and CE-SSFP. The difference 
was 0.5 ± 10 % (mean ± 2SD).
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Figure 17. Anterior STEMI. Corresponding 
left ventricular short axis views from a 
patient with anterior myocardial STEMI. 
MaR determined using (a) myocardial 
perfusion SPECT, (b) contrast-enhanced 
SSFP (CE-SSFP) at end-diastole, (c) infarct 
size images with LGE and (d) CE-SSFP 
at end-systole. It is clearly seen that the 
region of infarction does not correspond in 
size or endocardial extent to the region of 
myocardium at risk determined using either 
CE-SSFP or myocardial SPECT.
Figure 18. Inferior STEMI. Corresponding 
left ventricular short axis views from a patient 
with inferior STEMI. MaR determined 
using (a) myocardial perfusion SPECT, (b) 
contrast-enhanced SSFP (CE-SSFP) at end-
diastole, (c) infarct size images with LGE 
and (d) CE-SSFP at end-systole.
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Study IV: Contrast-enhanced SSFP compared with T2-weighted images
 
Myocardium at risk
A region with increased signal intensity measured by T2-weighted imaging and CE-SSFP 
was observed in all patients (Figure 19), yielding a mean MaR of 29 ± 11 % (range 12 – 65) 
and 32 ± 12 % (range 8 - 70) of the LV, respectively. There was a strong correlation between 
the two methods (r2 = 0.89, p < 0.01) (Figure 20). The Bland-Altman plot showed a limit of 
agreement between T2-weighted imaging and CE-SSFP, demonstrating a difference of -3.0 
± 3.9 % of the LV (p < 0.01). 
The CE-SSFP images were acquired on average 8 minutes (2-12) minutes after contrast agent 
administration. There was no change in CE-SSFP assessment of MaR compared with T2-
weighted imaging with time after contrast agent administration. Signal-to-noise ratio within 
the MaR was 156 ± 7 and 132 ± 10 for the T2-weighted imaging and CE-SSFP, respectively 
(mean ± SEM). The contrast-to-noise was 58 ± 3 and 27 ± 6 for the T2-weighted imaging 
and CE-SSFP, respectively (mean ± SEM). The contrast ratio between MaR and remote 
myocardium for T2-weighted imaging was 1.7 ± 0.3 compared to 1.5 ± 0.4 for CE-SSFP, 
which	was	not	statistically	significant	different.	
The interobserver variability was 5.0 ± 5.4 % of the LV for T2-weighted imaging and 0.1 ± 
6.2 % of the LV for CE-SSFP.
LAD LCx RCA
T2-Weighted 
Imaging
CE-SSFP
Late 
Gadolinium 
Enhancement
Figure 19. Single corresponding mid-ventricular short-axis images from a patient with an 
occlusion in the left anterior descending coronary artery (LAD), left circumflex coronary 
artery (LCx) and the right coronary artery (RCA), respectively. The epicardium is traced 
in green and the endocardium is traced in red. The hyperenhanced regions constituting 
the myocardium at risk (dashed arrows) and the infarcted myocardium (solid arrow) are 
traced in white. Note the similarity in location and extent of the affected region between 
T2-weighted imaging and contrast-enhanced steady-state free precession (CE-SSFP). Also 
note the significantly smaller infarction compared with the myocardium at risk, indicating a 
significant myocardial salvage accomplished through the acute reperfusion therapy.
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Figure 20. Relationship between T2-weighted imaging and contrast-enhanced steady-state 
free precession (SSFP) for myocardium at risk. Panel A: MaR by T2-weighted imaging 
versus CE-SSFP. Solid line = line of identity. Panel B: Bland-Altman graph showing the 
difference between MaR quantified by T2-weighted imaging and CE-SSFP versus the mean 
of the two methods. The difference between T2-weighted imaging and CE-SSFP was -3.0 ± 
3.9 %. Solid line = mean difference; dashed lines = ± 2SD.
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Figure 21. Relationship between T2-weighted imaging and contrast-enhanced SSFP for 
myocardial salvage. Myocardial salvage index measured by T2-weighted imaging versus 
myocardial salvage index measured by CE-SSFP. Solid line = line of identity.
Myocardial salvage index
The mean infarct size by LGE was 14 ± 11% (range 1 – 49) of the LV. The interobserver 
variability was 0.3 ± 2.2% of the LV. The infarct size was smaller in all patients when
compared with mean T2-weighted imaging (p < 0.01) and mean CE-SSFP (p < 0.01). When 
comparing the infarct size as determined through LGE in relation to MaR using T2-weighted 
imaging and CE-SSFP yielded a myocardial salvage index of 56 ± 22 % (range 15 – 93) and 
58	±	23	%	(range	16	–	95),	respectively	(Figure	21).	There	was	a	significant	correlation	(r2 = 
0.90, p < 0.01) between the myocardial salvage index measured using the two methods, with 
an	insignificant	bias	of	2.3	±	7.4%	of	the	LV.		
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GENERAL  DISCUSSION
This	 thesis	 presents	 novel	findings	 of	 short-	 and	 long-term	effects	 of	 postconditioning	 in	
patients with STEMI measuring infarct size with CMR, in relation to MaR. For the entire 
study population, the short- and long-term effects of postconditioning were neutral regarding 
infarct size and LVEF. However, among patients within the upper quartile of MaR smaller 
infarct sizes and improved LVEF were observed in the postconditioning group in comparison 
with the control group.
A	novel	method	 for	determination	of	MaR	with	 a	modified	 standard	CMR	sequence	was	
developed and validated against the reference standard method, SPECT. When comparing 
the new CMR sequence against the current standard edema CMR-sequence there was good 
correlation and the new method had a high accuracy regarding calculation of salvage index.
Myocardium at risk and CMR
Determination of MaR is of importance in clinical studies using infarct size or myocardial 
salvage as endpoints, in particular when studying small populations.114 The variation in 
MaR	is	usually	large	and	detection	of	differences	in	final	infarct	size	without	taking	MaR	
into consideration requires large sample sizes. The reference method for determination of 
MaR has been SPECT, a method with limited applicability in studies of acute interventions 
in patients with acute MI. Limited availability of isotopes and limited access to a gamma 
camera are the most important obstacles. The handling of and exposure to isotopes are other 
concerns. The need to develop new feasible and accurate methods for determination of MaR 
is therefore great. Previous attempts to investigate MaR with CMR focused on different T2-
weighted sequences several days after the index ischemia. It has been suggested that MaR 
can be estimated using T2-weighted imaging with short inversion time inversion recovery 
(STIR) or T2-prepared single-shot SSFP or a combination of both.134, 137, 155 156 T2-weighted 
imaging	as	a	tool	to	quantify	MaR	was	first	validated	in	humans	with	myocardial	perfusion	
SPECT as the reference140 and the method was subsequently used to demonstrate the rate of 
infarct evolution in man without confounding factors.141 The (ACUT2E) TSE-SSFP study 
showed promising results when using a hybrid method of T2-weighting with bright-blood 
contrast.135 
The reliability of CMR for the assessment of MaR and myocardial salvage index by means 
of T2-weighted sequences after reperfusion of an occluded coronary artery was recently 
questioned in a study using different ways to measure MaR with T2-weighted sequences.157 
There were differences found between all T2-weighted sequences compared with angiographic 
BARI score and from one T2-weighted technique to another. These factors might lead to a 
risk of over- or underestimating MaR and should be considered when using T2-weighted 
CMR as an assessment of MaR.
The	use	of	CE-SSFP	was	described	and	validated	for	the	first	time	in	Studies	III	and	IV.	CE-
SSFP showed a good correlation with SPECT (Study III) and there was an excellent correlation 
in determining MaR with CE-SSFP in the subsequent head-to-head comparison with the most 
commonly used T2-weighted CMR sequence (Study IV). Importantly, there was an equally 
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good correlation between the two methods, CE-SSFP and the T2-weighted sequence, when 
MaR was used for the assessment of the myocardial salvage index. The interobserver variation 
was indeed smaller for CE-SSFP than for the T2-weighted sequence. These observations are 
of considerable clinical importance allowing an accurate determination of MaR by means 
of CMR performed up to one week after the acute event. This will undoubtedly simplify the 
determination of MaR and salvage index in future studies of cardioprotection.
The mechanisms behind the enhanced myocardium observed in CE-SSFP are not completely 
understood. The contrast in SSFP images depends on the T2/T1 ratio.158 In the presence of 
paramagnetic gadolinium, T1 for the surrounding tissue is shortened. This is utilized for 
infarct visualization in T1-weighted LGE imaging, where the concentration of an extracellular 
gadolinium-based contrast agent is increased due to an increased distribution volume in 
irreversibly injured myocardium.126, 159-161 It has, however, also been shown that reversibly 
injured myocardium has an increased distribution volume after an ischemic episode. Hence, 
it is possible that the T2/T1 ratio in the entire MaR, including both reversible and irreversible 
injured myocardium, is affected by the presence of gadolinium. This might explain the 
increased signal intensity in the MaR as seen with CE-SSFP. Furthermore, it has been shown 
that the change in T1-relaxation rates before and after contrast agent administration remains 
constant from 4 to 29 minutes after administration in normal myocardium, as well as within 
the MaR and in infarcted myocardium.159	 These	 earlier	 findings	 indicate	 that	 the	 rate	 of	
exchange of contrast agent between the myocardium (normal and injured) and the blood 
pool	is	constant	and	much	faster	than	clearance	rate	in	the	kidneys	during	the	first	30	min	
after	 contrast	 agent	 administration.	Thus,	 these	findings	 can	 explain	why	 the	 relationship	
between MaR assessed using T2-weighted imaging and CE-SSFP did not change with time 
after contrast agent administration in Study IV and why the timing of CE-SSFP after contrast 
agent administration is not so critical. 
The pathophysiological basis for the enhanced myocardium observed using T2-weighted 
imaging is still not completely understood. Following an acute coronary occlusion, the 
ischemic myocardium shifts from aerobic metabolism to anaerobic glycolysis and ceases 
to contract. This failure of the energy-regulated membrane channels results in swelling of 
the	myocytes	 due	 to	 influx	 of	water	 and	 sodium.162 Furthermore, reperfusion leads to an 
inflammatory-like	 response	 increasing	 the	 amount	 of	 extracellular	 fluid.163 The increased 
water content in the affected myocardium is likely to explain the increased signal intensity 
compared with the non-affected myocardium as seen through T2-weighted imaging. 
Whether the increased water content is predominantly located in the intra- or extracellular 
space remains to be determined. The ischemic episode causes post-ischemic stunning and 
is associated with decreased contractility in the previously ischemic myocardium.164 It is 
reasonable to assume that the reduced contractility is associated with a decreased lymphatic 
drainage from the engaged myocardium, which may contribute to the increased water content 
one week after the acute event. 
Using T2-weighted imaging can sometimes be challenging, especially with regards to low 
signal-to-noise ratio, signal loss due to through-plane cardiac motion and/or increased signal 
from	stagnant	blood	flow	in	the	apical	part	of	the	LV.
These limitations can to a large extent be overcome by using CE-SSFP, since these 
shortcomings are not associated with SSFP imaging. Another advantage with CE-SSFP 
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imaging is that this technique is based on a multi-phase acquisition throughout the cardiac 
cycle. This enables tracking of the MaR and myocardial borders in multiple time frames, 
allowing delineation of both MaR and myocardial borders. Furthermore, CE-SSFP is ideal 
in situations where the time for scanning is limited e.g. due to heavy clinical workload or 
when handling an unstable patient. Gadolinium may then be injected prior to the examination 
and the imaging protocol can be shortened, since LV dimensions/function and MaR can be 
assessed from the same set of images. T2-weighted imaging for determination of MaR can, 
on the other hand, be performed in patients in whom a gadolinium-based contrast agent is 
contraindicated. Thus, there are several advantages of having access to more than one method 
for determination of MaR using CMR. 
Short-term effects of postconditioning in patients with STEMI 
The	first	groups	to	report	effects	of	postconditioning	in	patients	with	STEMI	were	Staat	et	
al57 and Laskey et al164, 165 who, in small populations, showed that postconditioning reduced 
the	release	of	CK,	a	surrogate	marker	for	infarct	size,	and	improved	coronary	flow	reserve	
and ST resolution. Thibault et al58 showed that postconditioning limited absolute infarct size 
and improved LVEF. They did not properly relate infarct size to the initial MaR, which is 
of importance as already discussed above. In this perspective, the recent report by Lønborg 
et al165 is of considerable interest. This group demonstrated that postconditioning resulted 
in a 19 % relative reduction of infarct size in relation to MaR. A problem is that there was a 
significant	difference	in	myocardial	mass	between	the	intervention	and	control	group,	which	
may	explain	most	of	 the	differences	 in	final	 infarct	size.	 In	addition,	 the	method	used	for	
estimating MaR, endocardial surface area, has limitations, in particular introducing a risk of 
underestimating MaR.144 
In Study I, infarct size after one week was related to MaR determined through left 
ventriculography.	 Interestingly,	 the	 slopes	 of	 the	 regression	 lines	 differed	 significantly	
between the control and the postconditioning groups when infarct size was analyzed as a 
function of MaR. This observation, suggesting a cardioprotective effect in patients with large 
MaR, led to further analysis of the infarct size among patients with MaR in the upper quartile, 
revealing	 that	 these	patients	 seemed	 to	benefit	 from	postconditioning.	Thus,	 their	 infarcts	
were smaller irrespective of whether the infarct was LAD-related or not. LVEF also differed, 
supporting	 a	 beneficial	 effect	 of	 postconditioning	 in	 patients	with	 large	MaR.	According	
to the regression analysis, a protective effect was detectable for MaR exceeding 36 %. In 
light of this observation it is important to note that the left ventricular MaR, determined 
from abnormally contracting segments, in previous studies was 35-40 %, which should be 
compared with 25 % in the present study in average. Collectively, these data might support 
the assumption that postconditioning is protective in patients with large MaR.
In	 contrast	 to	 previous	 reports,	 postconditioning	 did	 not	 influence	 the	 infarct	 size	 in	 all	
patients subjected to this procedure in Study I. This observation is, however, not the only one 
questioning	the	overall	efficacy	of	postconditioning.	A	recent	study	determining	infarct	size	
and LVEF as outcome measures in patients with STEMI reported neutral results in the entire 
group of postconditioned patients.166 Subgroup analysis even suggested harmful effects of 
postconditioning. Postconditioning was associated with lower myocardial salvage and lower 
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myocardial	salvage	 index.	Although	no	significant	differences	 in	absolute	 infarct	size	and	
LVEF were found between the groups at one week and six months after MI.
There are several differences of potential importance that may explain the discrepancies 
between trials evaluating the impact of postconditioning. In study I, infarct size was 
determined using CMR one week after the index event. This differs from the time of three to 
six months used in previous studies.58, 165 The rationale behind determining infarct size after 
one	week	in	Study	I	was	to	limit	the	possible	influence	of	LV	remodeling,	a	process	that	may	
influence	infarct	size.	To	determine	infarct	size	after	approximately	one	week	seems	optimal	
since the reduction of the hyperenhanced area is greatest during this period, balancing the 
early disappearance of the increased area of hyperenhancement against LV remodeling. To 
avoid	any	influence	of	spontaneous	reperfusion,	only	patients	with	TIMI	0	flow	were	recruited	
to	Study	I,	which	differs	from	previous	studies	accepting	a	flow	of	TIMI	grade	0-1.58, 165, 166 
Finally, the present postconditioning protocol was four cycles of 60 seconds reperfusion 
and 60 seconds of reocclusion. This is similar to the protocol used by Staat57, Thibault et 
al58 and Freixa et al166 but different from that applied by Lønborg et al.165 Although original 
observations suggested that brief cycles are optimal in small animal models (mice and rats), 
longer periods (30-60 seconds) may be more effective in larger species (pigs).56 A subsequent 
analysis	was,	however,	unable	to	define	an	optimal	postconditioning	protocol.167 
Long-term effects of postconditioning in patients with STEMI
Data on the long-term effects of postconditioning on infarct size and LVEF are sparse, in 
particular data based on the use of CMR. Thibault et al58 measured LVEF after 12 months 
of follow-up using echocardiography and reported a difference in favor of postconditioning. 
Lønborg et al172, who compared NYHA classes and ST-resolution, noted a trend towards 
better NYHA class and ST-segment resolution in patients subjected to postconditioning. 
Freixa et al166 reported no differences between groups in LVEF or infarct size using CMR 
after six months. The objective behind Study II, based on the results from Study I, was to 
evaluate the long-term effects of postconditioning on infarct size and LVEF, with a special 
focus on patients within the upper quartile of MaR. In line with the results from Study I, the 
slopes of the regression lines for infarct size and LVEF as a function of MaR continued to 
differ,	indicating	a	sustained	benefit	for	patients	with	large	MaR.	Taken	together,	available	
data indicate that postconditioning might be effective in patients with large MaR and that the 
effect is maintained during long-term follow-up. 
LV remodeling after myocardial infarction is an important prognostic factor for the 
progression to heart failure and subsequent mortality.168 Multiple factors contribute to the 
remodeling process including infarct size, MaR, microvascular obstruction, patency of the 
infarct-related artery and baseline LVEF.169, 170 Recent studies have used CMR as a tool 
for identifying predictors of remodeling in reperfused STEMI populations. Lund et al171 
demonstrated that an infarct size ≥24 % of the LV predicts remodeling with high sensitivity 
and	specificity.	Masci	et	al173, 174 concluded that infarct size rather than location predicted LV 
remodeling in STEMI patients and Eitel et al172 concluded that myocardial salvage index 
assessed using CMR predicts long-term clinical outcome in patients with STEMI. In Study 
II,	we	only	identified	nine	patients	who	met	the	remodeling	criteria	(>15	%	increase	of	ESV).	
The generally small infarct sizes are the most reasonable explanation for the absence of 
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remodeling. The end-diastolic sphericity index, which indicates LV cavity remodeling, did 
not change over time within either of the two groups, indicating that there was no overall 
adverse long-term remodeling in the present study population. In addition the, vast majority 
of the patients were treated with beta-blockers and ACE inhibitors, pharmacological agents 
known to counteract remodeling. Thus the group of patients with adverse remodeling was too 
small to permit an analysis of possible predictors for that process. 
 
Cardiac biomarkers
The use of cardiac biomarkers has until recently been the method of choice for quantifying 
infarct size.173 Troponin I and T, which are expressed exclusively in the heart, are components 
of the contractile apparatus of the cardiac myocyte. Troponins are present both in the cytosol 
and	myofibrils	of	the	myocyte.	Cardiac	troponin	I	and	T	are	currently	the	preferred	biomarkers	
for detection of myocardial necrosis, having supplemented older biomarkers such as CKMB 
because	of	superior	sensitivity	and	specificity.10 Peak and AUC of CKMB and troponin T 
correlate with infarct size measured with CMR.174 Recently, Turer et al175 concluded that high-
sensitivity troponin T could be detected after provoked ischemia in humans. These results 
may	 indicate	 that	cardiac	biomarkers	 reflect	 ischemic	myocardium	and	not	only	necrosis.	
In the present material, analysis of AUC of troponin T and CKMB had a better correlation 
with infarct size than with MaR, which is in accordance with the general opinion that cardiac 
biomarkers	reflect	the	extent	of	myocardial	necrosis.	
In Study I, there were no differences in the AUC levels of troponin T and CKMB between 
the two study groups, suggesting the absence of cardioprotection in an overall perspective. 
In contrast, the regression analysis comparing troponin T in relation to MaR in the upper 
quartile favored postconditioning. 
Study limitations
The	size	of	the	study	populations	may	have	been	too	small	for	the	detection	of	minor	benefits	
of postconditioning in Studies I and II. The number of patients was based on a power 
calculation assuming an absolute reduction of infarct size by 20 % of MaR. This level was 
chosen	as	representing	an	effect	that	should	be	of	clinical	value.	The	extent	of	the	final	infarct	
size	may	depend	on	several	factors,	besides	postconditioning,	which	are	difficult	to	control	in	
a clinical study. Known confounders are age, certain comorbidities e.g. kidney dysfunction, 
medication and pre-infarction angina known to precondition the myocardium as well as the 
presence of collaterals. The groups were well-matched regarding these factors, suggesting 
little impact on the primary endpoint. 
The angiographic method of MaR in Studies I and II may underestimate the actual MaR. 
These two studies were originally designed with this method for determination of MaR. Even 
though a new method of determining MaR was discovered during analysis of the examinations 
of Study I, it felt inappropriate to use this method in the patient material based upon which it 
was	first	described.	The	optimal	postconditioning	algorithm	is	not	known	and	there	may	be	
more effective algorithms than the one used, even if it is the most commonly applied. 
Peder Sörensson
44
Finally, since the signal intensities of the MaR and the remote myocardium varied between 
slices	and	between	patients,	making	it	difficult	to	choose	a	fixed	standard	deviation	of	signal	
intensities to differentiate MaR from remote myocardium, no semi-quantitative method was 
used to determine the MaR either on T2-weighted or CE-SSFP imaging. 
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FUTURE  PERSPECTIVES 
AND COMMENTS
CMR sequences
CE-SSFP	has	the	qualifications	to	become	a	useful	research	tool	in	trials	looking	at	myocardium	
salvage index by different interventions. Still, there are questions to be answered regarding 
mechanistic features of this technique. For instance, the reason for the hyperenhanced signal 
on SSFP is not fully understood and the kinetics of the contrast agent in the MaR needs to be 
addressed	further.	Whether	this	sequence	is	influenced	by	edema	reduction	induced	by	any	
cardioprotective intervention remains to be explored. Experimental studies addressing these 
questions are currently lacking but would be highly interesting. 
New CMR sequences that quantify image T1 or T2 with T1- and T2-mapping are currently 
available and may perhaps allow a robust visualization of MaR.176 This area of research is 
new and will require additional validation before becoming clinically useful.
Postconditioning 
Regarding postconditioning, several questions need to be addressed. The postconditioning 
algorithm was initially based on empirical observations in experimental studies.55 There 
is still no optimal algorithm that has proven superior in humans. Thus it is not surprising 
that different groups applied different algorithms. One study reported on less myocyte 
apoptosis by means of 60 rather than 30 seconds of reperfusion and ischemia.177 The optimal 
number of cycles is another unresolved issue in need of further investigation. Is two better 
than four and is four better than six? There is no test telling us whether we have reached 
maximum conditioning or not. A recent study in mice reported decreased infarct size with 
a prolonged postconditioning protocol lasting up to 30 minutes after the initial reperfusion. 
Thus,	 it	 provides	 conflicting	 evidence	 indicating	 that	 the	 time	window	 for	 protection	 by	
postconditioning may be longer than initially reported.41 Another unresolved question is 
which phase of the reperfusion is the most important: The reperfusion phase or the ischemia 
phase or are both equally important? Such information is necessary in order to optimize the 
postconditioning algorithm and number of cycles to be applied in future studies. 
The present results indicate that future attempts with postconditioning should primarily focus 
on patients with large MaR, i.e. with a substantial amount of myocardium to be salvaged. 
Changes	in	infarct	size	in	patients	with	small	MaR	may	be	difficult	to	detect	and	reduction	in	
their infarct size may be less important from a prognostic point of view. The follow-up period 
in Study II is presently the longest available, but there is a need for even longer periods. 
There is also a need  for studies looking not only at surrogate endpoints but also at clinically 
relevant outcome measures such as morbidity and mortality. This highlights the need for a 
large	multicenter	study	to	confirm	the	clinical	value	of	postconditioning.	
Translation from preclinical to clinical studies 
The search for an effective, easily applied and safe cardioprotective intervention is still 
only beginning. Although it certainly requires substantial efforts, it is of great importance to 
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further reduce the remaining morbidity and mortality related to acute MI. There are several 
potential explanations behind the major differences in success in preclinical and clinical trials 
in this sector.178 
In preclinical studies: various pharmacological agents are usually tested in one laboratory 
and in one or two animal models before being transferred to clinical trials. Most preclinical 
experiments are randomized but open, which may be a source of bias. Moreover the relevance 
of commonly used animal models, usually young, male animals without any comorbidities, 
may be misleading. 
In clinical studies: the dosages and administration times for drugs may cause problems. 
Intravenous instead of intracoronary infusions distal to the occlusion may explain the lack of 
success	in	some	trials.	Insufficiently	powered	(small)	studies	and	the	recruitment	of	patients	
with small MaR may also cause problems, as indicated by the present results. Moreover, 
different research centers have different protocols as regards anticoagulation/antiplatelet 
treatment, reperfusion techniques including stenting, and thrombus aspiration, which may 
introduce discrepancies in outcomes, such as infarct size and LVEF.
Future	attempts	to	find	new	effective	therapies	must	take	all	these	issues	into	consideration.	
An ideal study population for proof-of-concept trials would be patients with large MaR, with 
symptoms	for	less	than	six	hours,	no	pre-angina,	TIMI	flow	0	and	no	collaterals	and	then	later	
on expand the inclusion criteria to more general populations and multicenter studies with 
long-term follow-up. It would be reasonable to combine different cardioprotective modalities 
in such investigations considering the complexity of the reperfusion mechanism and the 
cross-talk between different pathways as outlined. A combination of remote conditioning and 
postconditioning would be interesting, with a potential for synergistic effects on the different 
pathways involved in the reperfusion injury. The chosen method should be easy to implement 
already in the ambulance and subsequently reinforced in the catheter laboratory. The future 
may also be to combine an optimal cocktail of different drugs targeting the different harmful 
effects of reperfusion. Currently there are >30 studies registered at ClinicalTrails.gov 
concerning	reperfusion	injury	and	myocardial	infarctions.	The	research	field	is	still	open	for	
new remarkable discoveries! 
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CONCLUSIONS
I.  Postconditioning did not affect infarct size, LVEF or cardiac biomarkers one week after 
STEMI in the entire study population. Infarct size was reduced and LVEF increased in 
the postconditioned patients with large MaR. 
II.  There was no difference in infarct size or LVEF between the postconditioning and 
control groups during 12 months of follow-up in the entire study population. In patients 
with large MaR, the early observations of a reduction in infarct size remained and these 
patients had a higher LVEF than patients in the control group at the 12-month follow-
up.
III.  CE-SSFP after one week accurately depicts MaR and correlates well with MaR 
determined with reference standard SPECT in patients with STEMI.
IV.  There was a strong correlation between MaR assessed by CE-SSFP and MaR assessed 
by T2-weighted imaging in reperfused patients with STEMI one week after the acute 
event. Both methods can be used to determine MaR and myocardial salvage.  
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